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Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease of the brain, 
which is characterized by a progressive loss of memory and spatial orientation. Only 
less than 5-10% of AD sufferers are familial cases due to genetic mutations in the 
amyloid precursor protein (APP) gene or presenilin (PS) 1 and 2 genes. The cause of 
sporadic AD (sAD) which covers > 95% of AD patients is still unknown. Current 
research found interactions between aging, diabetes and cognitive decline including 
dementia in general and in AD in particular. Disturbances of brain glucose uptake, 
glucose tolerance and utilization and impairment of the insulin/insulin receptor (IR) 
signaling cascade are thought to be key targets for the development of sAD.  
 
In the brain of AD patients, neural plasticity is impaired indicated by synaptic and 
neuronal loss. Adult neurogenesis (AN), the generation of functional neurons in the 
adult brain, may be able to restore neurological function deficits through the 
integration of newborn neurons into existing neural networks. The dentate gyrus of 
the hippocampus is one out of few brain regions where life-long AN exists. However, 
there is a big controversy in literature regarding the involvement of AN in AD 
pathology. Most animal studies used transgenic mice based on the Amyloid ß (Aß) 
hypothesis which primarily act as models for the familial form of AD. Findings from 
human post mortem AN studies were also inconstistent. In this thesis, we focused on 
the possible involvement of AN in the pathogenesis of the sporadic form of AD. 
Streptozotocin intracerebroventricularily (STZ icv) treated rats, which develop an 
insulin-resistant brain state and learning and memory deficits preceding Aß 
pathology act as an appropriate animal model for sAD. We used STZ treatment for 
both parts of my work, for the in vivo and in vitro study. 
 
In the first part of my thesis, my coworkers and I investigated STZ icv treatment 
effects on different stages of AN in an in vivo approach. Even if STZ icv treatment 
does not seem to considerably influence stem cell proliferation over a short-term (1 
                                                                                    Summary 
II 
 
month after STZ icv treatment) as well as in a long-term (3 months after STZ icv 
treatment) period, it results in significantly less immature and newborn mature 
neurons 3 months after STZ icv treatment. This reduction detected after 3 months 
was specific for the septal hippocampus, discussed to be important for spatial 
learning. Subsequently we performed co-localization studies with antibodies 
detecting BrdU (applied appr. 27 days before sacrifice) and cell-type specific markers 
such as NeuN, and GFAP, we found that STZ treatment does not affect the 
differentiation fate of newly generated cells. Phenotype analysis of BrdU-positive 
cells in the hilus and molecular layer revealed that some of the BrdU-positive cells 
are newborn oligodendrocytes but not newborn microglia. 
 
In the second part of my thesis I worked with cultured neural stem cells (NSCs) 
isolated from the adult rat hippocampus to reveal STZ effects on the proliferation of 
of NSCs, and on the survival and differentiation of their progeny. Furthermore, this in 
vitro approach enabled me to study cellular mechanisms underlying the observed 
impaired neurogenesis in the hippocampus of STZ-treated rats. In contrast to our 
findings of the STZ icv in vivo study we revealed that STZ supplied with the cell 
culture medium inhibits the proliferation of NSCs in a dose-dependent and 
time-dependent manner. Moreover, performing immunofluorescence studies with 
antibodies detecting cell-type specific markers after triggering NSCs to differentiate, 
we could show that STZ treatment affects the number of newly generated neurons 
but not of astrocytes. Analyzing newborn cells starting to differentiate and migrate I 
was able to demonstrate that STZ has no effect on the migration of newborn cells. 
Trying to reveal cellular mechanisms underlying the negative influence of STZ 
on hippocampal AN, we performed qRT-PCR and immunofluorescence staining 
and thus could show that in NSCs the expression of glucose transporter 
(GLUT)3 mRNA as well as IR and GLUT3 protein levels are reduced after STZ 
treatment. Therefore, the inhibition of the proliferation of NSCs may be (at least 
partially) caused by these two molecules. Interestingly, the effect of STZ on 
differentiating cells was shown to be different, as IR protein expression was not 
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significantly changed but GLUT3 protein levels were decreased in consequence of STZ 
treatment.  
 
In summary, this project delivered further insights into the interrelation between AN 
the sporadic form of sAD and thus provides a basis of new therapeutic approaches in 
sAD treatment through intervening AN. Discrepancies between the results of the two 
parts of my thesis, the in vivo and in vitro part, were certainly caused to a certain 
extent by the missing microenvironment in the in vitro approach with cultured NSCs.  
Future studies e.g. using co-culture systems could at least minimize the effect of a 
missing natural microenvironment of cultured NSCs, so that the use of an in vitro 








Die Alzheimer-Krankheit (AK) ist die häufigste neurodegenerative Erkrankung 
weltweit. Nur etwa 5 bis 10% der Betroffenen leiden an der familiären Form, die auf 
bestimmten Mutationen in einzelnen Genen, wie z.B. dem Amyloid precursor protein 
(APP)-Gen, zurückzuführen ist. Die Ursache der sporadischen Form der AK  (sAK), 
die mehr als 95% der Betroffenen ausmacht, ist hingegen noch weitgehend 
unbekannt. Jüngste Erkenntnisse weisen auf eine Wechselwirkung von hohem Alter, 
Stoffwechselkrankheiten wie z.B. Diabetes, und kognitiven Defiziten, welche eine 
Demenz im Allgemeinen und die Alzheimer-Krankheit im Besonderen kennzeichnen, 
hin. Deshalb werden Störungen in der Glukoseaufnahme, in der Glukosetoleranz, und 
in der Funktion des Insulin/Insulinrezeptorsignalweges als Schlüsselelemente für die 
Entstehung einer sAK angesehen. 
 
Die neuronale Plastizität der Gehirne von AK-Patienten ist stark eingeschränkt, was 
sich vor allem durch den Verlust von Synapsen als auch durch den Verlust ganzer 
Nervenzellen zeigt. Die adulte Neurogenese (AN), die Neubildung von Neuronen im 
Gehirn von erwachsenen Individuen, könnte durch den Einbau neu gebildeter 
Neurone in existierende neuronale Netzwerke eine wichtige Rolle bei der 
Regenerierung  neurologischer Defizite spielen. Der Gyrus dentatus im 
Hippocampus ist eine der wenigen Gehirnregionen, in welcher lebenslang AN 
stattfindet. Jedoch ist noch unklar, ob eine veränderte AN an der Pathogenese der AK 
beteiligt ist. Es wurden bereits viele Untersuchungen zur AN in Tiermodellen 
durchgeführt, wobei die überwiegende Anzahl von bisher verwendeten Tiermodellen 
auf der Amyloid ß-(Aß) Hypothese basieren, und somit primär Modelle für die 
familiäre AK darstellen. Studien mit humanem post mortem-Gewebe gaben bisher 
jedoch auch noch keine klaren Hinweise auf die mögliche Bedeutung einer 
veränderten AN für die AK. 
 
In dieser Thesis sollte die Rolle der AN für die Pathogenese der sAD untersucht 
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werden. Dafür wurden Ratten mit Streptozotocin intracerebroventrikulär (STZ icv) 
behandelt. Diese so behandelten Ratten gelten als Tiermodell für die sAK, da sie 
bereits kurze Zeit nach ihrer STZ icv-Behandlung kognitive Defizite zeigen, ihr Gehirn 
eine Insulin-Resistenz entwickelt, und etwas später dann auch erste Anzeichen einer 
Aß-Pathologie nachweisbar sind. 
 
Im ersten Teil dieser Arbeit wurde in einem in vivo-Ansatz der mögliche Einfluss einer 
STZ icv-Behandlung auf die verschiedenen Stadien der AN untersucht. Wir konnten 
zeigen, dass 1 Monat nach STZ icv-Behandlung weder die Proliferation neuraler 
Stammzellen (neural stem cells, NSCs) noch die Bildung junger Neurone verändert 
war, dass aber nach 3 Monaten signifikant weniger junge unreife und auch reife 
Neurone entstanden sind. Diese reduzierte Anzahl neu gebildeter Neurone konnte 
nur im septalen Teil des Hippocampus, dem eine bedeutende Rolle beim räumlichen 
Lernen zugesprochen wird, nachgewiesen werden. Durch eine quantitativ 
ausgewertete Ko-Lokalisationsstudie mit Antikörpern gegen Bromodesoxyuridin 
(BrdU) (mehrmalige i.p.-Gabe 27 Tage vor Gewebeentnahme) und 
zelltyp-spezifischen Markern wie dem Neuronenmarker NeuN und dem Marker für 
Astrozypen GFAP konnten wir zeigen, dass die STZ icv-Gabe nur die Anzahl der neu 
gebildeten Neuronen, aber nicht die Differenzierungsrichtung der neu gebildeten 
Zellen verändert.  Eine qualitative Phänotypanalyse BrdU-positiver Zellen ergab 
außerdem, dass im Hilus und in der Molekularschicht des Gyrus dentatus lokalisierte 
BrdU-positive Zellen neu gebildeten Oligodendrozyten, aber nicht neu gebildeten 
Mikrogliazellen, zugeordnet werden konnten.  
 
Im zweiten Teil meiner Arbeit habe ich NSCs aus dem adulten Hippocampus isoliert 
und kultiviert, um auch auf diese Art und Weise mögliche Effekte von STZ auf die 
Proliferation von NSCs als auch auf das Ü berleben und die Differenzierung von neu 
geborenen Zellen zu untersuchen. Ziel dieser in vitro-Studie war eine genauere 
Analyse der durch STZ-Gabe ausgelösten grundlegenden zellulären Mechanismen. Im 
Widerspruch zu den Ergebnissen der in vivo-Studie konnte ich einen Dosis- und 
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Zeit-abhängigen negativen Effekt von STZ auf die Proliferation der NSCs zeigen. 
Darüber hinaus führte die Zugabe von STZ zum Medium letztendlich zu einer 
verringerten Bildung von Neuronen, die Neubildung von Astrozyten zeigte sich 
jedoch unverändert. In einem Test zur Untersuchung der Migration neu gebildeter 
Zellen konnte ich keinen Einfluss von STZ auf die Migration nachweisen. Weitere 
Analysen ergaben, dass die verringerte Proliferation der NSCs im Zusammenhang mit 
einer reduzierten mRNA- als auch Protein-Expression des 
Glukosetransporters(GLUT)3 und mit reduzierten Insulinrezeptorkonzentrationen 
stehen könnte.  In sich differenzierenden Zellen jedoch wurde neben einer ebenfalls 
reduzierten GLUT3- Proteinexpression keine veränderte Insulinrezeptorenausstattung 
detektiert.  
 
Zusammenfassend gibt die vorliegende Arbeit mithilfe des in vivo- als auch in 
vitro-Ansatzes Hinweise auf eine Bedeutung der hippocampalen AN für die 
Entstehung der sAK und bietet dadurch Ansatzpunkte für neue therapeutische 
Ansätze. Die im in vivo- und in vitro-Ansatz erzielten unterschiedlichen Resultate, die 
sicherlich zum Teil durch die fehlende Mikroumgebung der NSCs und sich 
differenzierenden Zellen im in vitro-Ansatz verursacht wurden, können in Zukunft z.B. 
durch Ko-Kulturen zumindest verringert werden, so dass mithilfe von in 
vitro-Ansätzen grundlegende zelluläre Mechanismen einer STZ-Effekts in Zukunft 
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1.1 Alzheimer’s disease 
 
1.1.1 Alzheimer`s disease, its classification and prevelance 
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease of the 
brain which affects people in several ways, including memory (Ballard et al., 2011), 
judgment (Marson et al., 2000), language (Murdoch et al., 1987), problem-solving 
(Willis et al., 1998), executive ability (Binetti et al., 1996) as well as personality 
(Bozzola et al., 1992). AD typically develops slowly and gradually gets worse over the 
course of several years. In early stages, symptoms can be observed by friends, family 
or colleagues including greater difficulty performing tasks in social interaction, 
increasing trouble with planning or organizing and hard learning new skills. Many 
people in the early stage also change mood, like experiencing increased anxiety. Then 
cognitive impairment becomes evident with the disease development. With the 
symptoms continue to worsen, the ability to perform basic activities of daily life is 
decreased, major personality and behavioral changes were also found. AD is fatal and 
normally leads to death (Reisberg et al., 1982). 
 
Only less than 5-10% of AD sufferers are familial cases due to genetic mutations in 
the amyloid precursor protein (APP) gene or presenilin (PS) 1 and 2 genes, and 
inheriting any of these genetic mutations ensures the development of AD (Correia et 
al., 2011). Mutations in the PS1 and PS2 genes account for as much as 50% of all 
familial AD (fAD) cases (Tandon and Fraser, 2002). More than 30 mutations in the 
APP gene and more than 180 mutations in PS1 and PS2 genes have been identified so 
far (Bi, 2010). All of these mutations cause overproduction of Aβ (Lemere et al., 
1996, Eckman et al., 1997, Takeda et al., 2004). The disease symptoms with familial 
AD patients tend to develop before age 65, sometimes as early as age 30 (Reitz et al., 
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2011). The cause of the late-onset sporadic AD (sAD) which affects > 95% of AD 
patients is still unknown. The symptoms of most of the sAD cases begin after 65 
years of age (2014 Alzheimer's Disease Facts and Figures). 
 
Worldwide, nearly 44 million people have AD or related dementia (Alzheimer’s 
Disease International) and places a considerable burden on society (Qiu et al., 2009). 
North America and Western Europe exhibit the highest prevalence and incidence 
rate compared to other developed and developing countries (Alzheimer’s Disease 
International). In the US, estimated 5.2 million Americans of all ages had AD in 2014 
(2014 Alzheimer's Disease Facts and Figures).  
 
1.1.2 Pathological features of AD   
The two most prominent neuropathological hallmarks of AD are extracellular senile 
plaques which mainly consist of the amyloid-β (Aβ) and intracellular accumulation of 
tau protein (Braak and Braak, 1991). Aβ, peptides of 36-43 amino acids, is derived 
from the sequential cleavage of the APP by the β- and γ-secretases which form a 
multi-protein complex comprising PS, presenilin enhancer 2 (PEN-2), anterior 
pharynx-defective 1 (APH-1) and nicastrin (Nunan and Small, 2000). Depend on the 
different cleavage site for γ-secretases, varying lengths of Aβ peptides have been 
observed, such as Aβ40 and Aβ42 (Fortini, 2002). Aβ40 is relatively benign, but Aβ42 
aggregates more rapidly into neurotoxic oligomer with a β sheet structure and then 
form to plaques (Burdick et al., 1992, Bloom, 2014). Senile plaques consist of 
degenerating neuronal processes with tau paired helical filaments surrounding with 
deposits of Aβ (Davies et al., 1988, Cras et al., 1991). Intracellular aggregates of the 
hyperphosphorylated microtubule-associated protein tau form insoluble tangles, and 
are thought to be causally related to neuronal apoptosis (Goedert et al., 1989). Even 
if the amyloid cascade hypothesis is considered to be most popular hypotheses in AD 
research, cognition and memory decline in AD is not correlated with plaques (Nelson 
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et al., 2012). The NFTs of AD have a relatively strong correlation with cognitive 
function than amyloid plaques, but it is not unusual to see tangles in the brain of 
healthy, even as young as thirty years of age (Braak and Del Tredici, 2011).  
 
Recent evidence indicates that AD neuropathology begins in brainstem nuclei, that 
send diffuse projections to a variety of brain regions (Braak and Del Tredici, 2012). As 
shown by Braak and Del Tredicie proximal axons of some coeruleus neurons in the 
brain of remarkably young individuals already exhibit nonfibrillar abnormal tau 
(Braak and Del Tredici, 2011). Moreover, according to the previously proposed 
seeded polymerization theory intracellular oligomeric Aβ in brainstem neurons 
possibly acts as the initiator of plaque formation in other brain regions such as the 
cerebral cortex and hippocampus and thus initiates the production of plaques in AD 
brains (Muresan and Muresan, 2008). This hypothesis of is supported by the in vitro 
study of Muresan and Muresan (2008) who found that brainstem-derived neuronal 
cells – but not cortical or hippocampal neurons – show large amounts of Aß 
accumulated at the terminals of their processes (Muresan and Muresan, 2008). The 
earliest stage of cortical neurofibrillary pathology emerges in the superficial 
entorhinal layer pre-α of the trans-entorhinal region (Braak and Braak, 1985). With 
the disease becomes worsen, the neurofibrillary pathology can be seen in all areas of 
the isocortex including sensory and motor cortex fields (Braak and Braak, 1991). 
 
However, he level of synapse loss in AD brains demonstrates a higher correlation 
with decreased cognitive function than plaque and tangles development (Terry et al., 
1991), suggesting disappearance of synapses is a key event in early cognitive decline 
(Gylys et al., 2004). Neurons in several brain regions are affected in AD, such as in the 
cerebral cortex which is involved in conscious thought and language, and 
hippocampus that is essential for the consolidation of information from short-term 
memory to long-term memory and spatial navigation. (Davies et al., 1980). The 
biochemical and molecular abnormalities which have been found in the AD patient’s 
brain include increased activation of apoptotic genes and signaling pathways (Sajan 
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et al., 2007), impaired glucose utilization and energy metabolism (Fukuyama et al., 
1994), mitochondrial dysfunction (Hirai et al., 2001), increased oxidative stress 
(Gibson et al., 1999), acetylcholine transmission dysfunction (Perry et al., 1978), 
altered Insulin/Insulin receptor (IR) signaling cascade (Ronnemaa et al., 2008), and 
DNA damage (Anderson et al., 1996).  
 
1.1.3 Risk factors 
Many factors contribute to the likelihood of developing AD and the greatest known 
risk factor is advancing age. The risk of developing this disease doubles every 5 years 
(Brentjens and Saltz, 2001) after the age of 65, and about one-third of people aged 
85 and older have AD (2014 Alzheimer's Disease Facts and Figures). When AD runs in 
families, heredity, shared environmental and lifestyles factors may play a role (Donix 
et al., 2012).  
 
Growing evidence suggests that the health of the brain is closely related to the 
overall health of heart and blood vessels. Many factors that increase the risk of 
cardiovascular disease are also associated with a higher risk of developing AD or 
other types of dementia (Newman et al., 2005) such as smoking (Merchant et al., 
1999), alcohol consumption (Graves et al., 1991), obesity (Kivipelto et al., 2005), 
diabetes (Biessels and Kappelle, 2005), high cholesterol and hypertension in midlife 
(Kivipelto et al., 2002). The gene for Apolipoprotein E (APOE) protein, which 
mediates cholesterol metabolism (van den Elzen et al., 2005), but is also critically 
involved in the vivo conversion of “normal” Aβ into Aß which contains high β-sheet 
content and associated with cellular toxicity (Holtzman, 2001) is an interesting 
candidate for AD research. 
   
Already in 1993 Strittmatter et al showed that individuals which carry the ε4 form of 
the Apolipoprotein E (APOE) gene have a higher risk for developing AD than carriers 
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of the ε2 and 3 alleles (Saunders et al., 1993, Strittmatter et al., 1993, Breitner et al., 
1999). Researchers estimate that between 40 and 65 percent of people diagnosed 
with AD have one or two copies of the APOE ε4 gene variant (Hauser and Ryan, 2013). 
Interestingly, women with an APOE ε4/ε4 genotype have a 45% probability of 
developing AD by the age of 73, whereas men have only a 25% risk (Breitner et al., 
1999). Up to now the role of APOE ε4 in AD pathogenesis is not fully elucidated. 
    
In recent years it has been more and more accepted that disturbances of brain 
glucose uptake, glucose tolerance, glucose utilization and impairment of the 
insulin/IR signaling cascade are key targets for the neuropathology of sAD (Grunblatt 
et al., 2007, de la Monte, 2009, Salkovic-Petrisic et al., 2009, Correia et al., 2011, 
Talbot et al., 2012). As key energy source in the body, glucose is even more important 
in the brain and it acts as the primary source of energy for brain cells (Pardridge, 
1983). It is taken up into cells by facilitated diffusion mediated by a series of glucose 
transporter family (Duelli and Kuschinsky, 2001). Glucose transport across the 
blood-brain barrier (BBB) into brain is fascilitated by GLUT1 (Leybaert et al., 2007). 
Two different GLUT1 isoform, one with a molecular weight of 45 kDa and the other 
one with 55 kDa, exist in the brain (Cunnane et al., 2011). The 55 kDa GLUT1 isoform 
is located at the luminal and the abluminal membranes of the brain endothelium 
cells and is responsible for the glucose transport across the BBB (Gerhart et al., 1989). 
Then, Glucose is taken up by astrocytes, oligodendroglia, microglia as well as neurons. 
It is transported into astrocytes via the 45 kDa GLUT1 isoform and exhibits highest 
concentration in astrocytic end feet and astrocytic processes surrounding synapses 
(McCall et al., 1996). The 45 kDa form of GLUT1 is also localized in oligodendroglia 
but not microglia (Yu and Ding, 1998). On the other hand, GLUT3, another major 
important glucose transporter in the brain which displays higher transport rates than 
GLUT1 (Dienel, 2012), facilitates neuronal glucose uptake (Simpson et al., 2007). 
Astrocytes, oligodendrocytes and endothelial cells have not been found to express 
GLUT3 (Haber et al., 1993). GLUT5 is expressed in microglial cells (Payne et al., 1997). 
GLUT1, 3 and 5 are all insulin-independent glucose transporters (Banks et al., 2012). 
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GLUT4, on the other hand, is an insulin-regulated glucose transporter which is found 
to be expressed in some specific neuronal cells in the cerebellum, hypothalamus and 
hippocampus (Grillo et al., 2009). Insulin stimulates the translocation of GLUT4 to 
neuron membranes and increases in glucose uptake (Grillo et al., 2009). Radioactive 
in situ hybridization for GLUT3 combined with immunocytochemistry for GLUT4 
demonstrates the presence of GLUT3 mRNA in GLUT4-positive cells in the cerebral 
cortex, hippocampus, medial septum and cerebellum (Apelt et al., 1999). It is 
believed that GLUT4 plays a role in the brain by rapidly providing additional glucose 
to neurons under conditions of high-energy demand (El Messari et al., 1998). 
 
Numerous studies have found that individuals with diabetes, both type 1 diabetes 
mellitus (T1DM) and T2DM, have a lower level of cognitive function and are at higher 
risk for dementia than individuals without diabetes (Ott et al., 1999, J et al., 2009). 
The possible physiological and molecular mechanisms are linked to glycemia, insulin 
resistance, oxidative stress, advanced glycation endproducts, inflammatory cytokines, 
as well as macrovascular and microvascular disease (Whitmer, 2007). In the brain of 
T2DM patients, more hippocampal and amygdalar atrophy was shown compared to 
elderly subjects of the same age without T2DM using magnetic resonance imaging 
(MRI) (den Heijer et al., 2003).  
 
Lots of studies suggest Alzheimer-like changes found in different animal models for 
diabetes such as the streptozotocin (STZ) ip injection rat model (Biessels et al., 1998), 
T1DM BioBreeding/Worcester (BB/W) rat model (Li et al., 2002), T2DM BBZDE/Wor 
rats model (Li et al., 2007), and high-fat diet feeding mouse model (Moroz et al., 
2008). High-fat diet feeding T2DM mouse model shows AD-like neurodegeneration 
with histopathological, molecular and biochemical brain abnormalities like increased 
levels of tau and Aβ, brain atrophy, insulin resistance, oxidative stress (Moroz et al., 
2008). Spontaneously type 1 diabetic BB/W rats show progressively impaired 
cognitive function associated with suppressed insulin/ insulin-like growth factor-1 
(IGF-1) expression and increased neural apoptosis in hippocampus which can be 
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prevented by treating with insulinomimetic C peptide(Li et al., 2002). Neural loss also 
found in T2DM BBZDE/Wor rats is associated with increased dystrophic neuritis, APP, 
β-secretase, Aβ and decreased insulin and IGF-1 receptor expression (Li et al., 2007). 
In diabetic rats induced/produced by STZ ip injections impaired hippocampal 
plasticity as well as impaired cognitive performances has been found (Biessels et al., 
1998).  
 
Postmortem studies suggest disturbances of cerebral glucose metabolism and insulin 
receptor (IR) signal transduction in AD (Hoyer, 2004) which are pathophysiological 
features of T2DM (Goldstein, 2002). IR signaling impairment triggers a chain reaction, 
including the decreased level of insulin receptor substrate (IRS) and altered 
downstream signaling pathways (Salkovic-Petrisic et al., 2009). This altered IR 
signaling pathway could result in impairment of glucose/energy metabolism, 
phosphorylation of tau protein as well as accumulation of intraneuronal Aβ (see Fig. 
1) (Salkovic-Petrisic et al., 2009). In brain, advanced AD is associated with strikingly 
reduced levels of insulin and IGF-1 polypeptide and receptor genes (Steen et al., 
2005). The signaling pathways which mediate insulin/IGF-1-stimulated neuronal 
survival, energy metabolism and mitochondrial functions were disturbed in AD (Fig.1) 
(Steen et al., 2005). Peripheral insulin resistance without T2DM is a risk factors for AD 
within 3 years and after 3 years the risk is no longer increased (Schrijvers et al., 2010). 
In the brain of AD patients, glucose utilization abnormalities happen both, in fAD 
(Hoyer and Nitsch, 1989) and sAD cases (Hoyer et al., 1991). So, insulin resistance 
defined as reduced cellular responsiveness to insulin which is key feature of T2DM 
(Goldstein, 2002) also occurs in the AD brain. Abnormalities in insulin/IGF-1 
pathways in AD were quite similar to the effects of diabetes. Besides, AD 
neuropathology is shown to be stronger in AD patients with diabetes compared to 
AD patients without diabetes, including larger plaques and more tau positive cells 
(Valente et al., 2010). All these findings suggest AD may represent a neuro-endocrine 
disorder and some researchers even name it “Type 3 diabetes” (Steen et al., 2005, de 
la Monte and Wands, 2008). According to this hypothesis, using antidiabetes drugs 
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may reduce or even prevent AD-type neurodegeneration. Some antidiabetes drugs 
are based on glucagon-like peptide-1 (GLP-1) that is an incretin hormone which can 
facilitate insulin signaling (Drucker et al., 2010). Liraglutide, a long-acting GLP-1 
agonist for treatment of T2DM, can reverse memory impairment, synaptic loss and 
reduce plaque load in aged APP/PS1 mice, a transgenic model of Alzheimer's disease 
(McClean and Holscher, 2014). Another GLP-1 analogue (Val8)GLP-1 is shown to 
enhance neuronal stem cells proliferation, whereas the GLP-1 receptor antagonist 
exendin (9-39) impairs spatial learning (McGovern et al., 2012).  
 
 
Fig.1. Proposed mechanism of the neuronal insulin receptor signaling cascade impairment 
(Salkovic-Petrisic et al., 2009).  
Insulin receptor (IR) signaling impairment triggers a chain reaction, including the level of insulin 
receptor substrate (IRS) and downstream signaling pathway, like phosphatydilinoditol 3 kinase 
(PI3-K) pathway. IR signaling pathway impairment induced PI3-K dysfunction leads to reduced 
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protein kinase B (Akt/PKB) which involved in glucose/energy metabolism regulation, insulin 
degrading enzyme (IDE) activity regulation as well as phosphorylation and inactivation of 
glycogen synthase kinase 3α/β(GSK-3 α/β). Dashed lines/arrows represent reduction or inhibition 
of the processes while solid lines/arrows represent stimulation of the processes. 
 
1.2 Animal models for Alzheimer’s disease 
1.2.1 Transgenic mouse models  
As described in 1.1.2, AD is characterized by the accumulation of Aβ plaques and 
NFTs. As the amyloid cascade hypothesis and the tau protein hypothesis are 
considered to be most popular hypotheses for AD most animal models are based on 
them. 
 
After the discovery of certain mutations in the APP gene of fAD patients, researchers 
tried to produce transgenic mouse models based on the overexpression of APP 
containing fAD mutations. Game et al. first reported a successful transgenic AD 
model using a platelet derived growth factor-β (PDGF) promoter driven human APP 
gene containing an FAD associated mutation (V717F) (Games et al., 1995). These 
PDAPP mice exhibit high human APP expression and exhibit extracellular Aβ 
deposition, dystrophic neuritis, reactive astrocytes, activated microglia, as well as 
loss of synaptic and dendritic density (Games et al., 1995). PDAPP mice showed 
cognitive deficits at a young age, including spatial working memory deficits at four 
months of age assessed by the Morris water maze (Hartman et al., 2005) and 
recognition memory deficit at six months of age assessed by novel object recognition 
(Dodart et al., 1999). Hsiao et al. overexpressed a human APP transgene containing 
the Swedish fAD mutation (K670N/M671L) driven by a hamster prion promoter 
(termed Tg2576 mice) (Hsiao et al., 1996). These mice develop numerous Aβ plaques 
by 11-13 months of age, and oxidative damage and synaptic plasticity changes could 
be found (Hsiao et al., 1996). Impaired learning and memory in Tg2576 mice have 
                                                                                  Introduction 
10 
 
been reported at less than six months (Hsiao et al., 1996). Subsequently, many other 
transgenic lines were developed with similar methods as used for the generation of 
PDAPP and Tg2576 mice such as TgCRND8 mice [carrying the human APP 695 (hAPP) 
including the “Swedish” and “Indiana” mutations (hAPPSw,Ind mice) controlled by 
the Syrian hamster prion promoter] (Chishti et al., 2001), APP 23 mice [carrying hAPP 
with Swedish mutation] (Sturchler-Pierrat et al., 1997). PS1 and PS2 fAD mutant 
transgenic lines were also developed, but single transgenic PS1 or PS2 mice do not 
develop Aß plaques (Holcomb et al., 1998). PS1/APP double transgenic mice, 
generated by crossing human PS1 with A246E mutation and APP with Swedish 
mutation (APPSwe), show elevated Aβ 42 peptide and numerous plaques by nine 
months of age (Borchelt et al., 1997) earlier than PDAPP and Tg2576 mice. All these 
mice generate Aβ amyloidosis and show a variety of neuropathological and 
behavioral defects including neural and synaptic loss, activated astrocytes and 
microglia as well as learning and memory deficits. However, in these mice model, 
neurofibrillary tangles are not present, which is another hallmark of AD. 
 
Besides the transgenic mice with fAD mutations in APP and PS1/2, AD models were 
also produced which are based on the tau protein hypothesis. The first tau transgenic 
mouse model expressed the longest human wild-type (WT) tau isoform in neurons 
where pre-tangle formations and hyperphosphorylation of tau was observed (Gotz et 
al., 1995). Then, other Tau models were produced by the expression of human 
mutant P301L and P301S Tau in mice which then develop NFTs, neural loss, brain 
atrophy, impaired spatial learning and memory (Lewis et al., 2000, Yoshiyama et al., 
2007, Takeuchi et al., 2011). These tau transgenic models are valuable tools in AD 
research and their pathology such as synapse and neuronal loss, NFTs formation, 
impaired learning and memory or inflammation are features of AD. However, Aβ 
amyloidosis is not successfully present in Tau model. 
 
In order to develop a mouse dealing with both AD hallmarks, amyloid plaques and 
NFTs, triple-transgenic mice were generated in 2003 harboring PS1M146V, APPSwe and 
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TauP301L(Oddo et al., 2003). Age-related, progressive neuropathology including 
amyloid plaques and tangles are presented successfully in these mice (Oddo et al., 
2003, Billings et al., 2005). In triple-transgenic mice, synaptic dysfunction and 
cognitive impairment precedes the accumulation of pathological lesions (Oddo et al., 
2003, Billings et al., 2005). However, triple-transgenic model are still based on fAD 
mutations which had been found in only less than 5% of AD sufferers. Most AD 
patients do not have any mutations in their APP, PS1 and PS2 genes.  
 
1.2.2 The Streptozotocin intracerebroventricular rat model 
As already discussed in 1.1.3, diabetes is a risk factor for AD and diabetes as well as 
AD share lot of similarities in molecular, biochemical and mechanistic abnormalities 
(Hoyer, 2004, Nicolls, 2004, Steen et al., 2005). Based on these facts, researchers 
developed an experimental animal model by intracerebroventricular (icv) application 
of streptozotocin (STZ) in order to mirror an insulin resistant brain state (Fig.2) 
(Lannert and Hoyer, 1998, Grunblatt et al., 2007, Salkovic-Petrisic et al., 2009). STZ 
[2-deoxy-2-(3-methyl-3-nitrosourea)-1-D-glucopyranose] is a naturally occurring 
compound produced by soil bacterium Streptomyces achromogens which is 
particularly toxic to the insulin-producing β cells of the pancreas in mammals (Eileen 
Dolan, 1997). It is used in medicine for treating certain cancers of the Islets of 
Langerhans (Murray-Lyon et al., 1968, Brentjens and Saltz, 2001) and is used in 
research to produce animal models for T1DM applying high doses of STZ via i.p. 
injections (Like and Rossini, 1976) and T2DM with i.p. injection(s) of low STZ doses 
(Reaven and Ho, 1991, Wang and Gleichmann, 1998, Reed et al., 2000). High dose 
STZ treatment destroys β cells through methylating DNA, activating 
polyADP-ribosepolymerase (PARP) and then depleting intracellular NAD+ (Szkudelski, 
2001). Multiple low doses of STZ could reduce the expression of the glucose 
transport protein 2 (GLUT2) and this reduction results in the failure of β cells to 
respond to glucose, and causes peripheral insulin resistance by damage of IR 
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Fig.2. Insulin resistance in the brain after STZ icv treatment (modified from (Salkovic-Petrisic et 
al., 2013b)  
Under the physiological condition, the uptake of glucose via glucose transporter GLUT4 is 
regulated by the insulin receptor (IR) signaling downstream the phosphatidyl inositol-3 kinase 
(PI-3K) pathway. IR signaling as well as GLUT3 has been found damaged by 
intracerebroventricular administration of streptozotocin (STZ icv). 
 
Regarding the close relationship between diabetes and AD as well as insulin 
resistance in the brain after STZ icv treatment (Fig.2), STZ icv treated rats are 
proposed to be an animal model for sAD (Lannert and Hoyer, 1998, Grunblatt et al., 
2007, Salkovic-Petrisic et al., 2009). STZ icv treatment is shown to cause deficits 
in learning and memory already 2-4 weeks after STZ icv injections (Mayer et al., 
1990, Lannert and Hoyer, 1998, Ishrat et al., 2006, Salkovic-Petrisic et al., 2006, 
Khan et al., 2012, Salkovic-Petrisic et al., 2014). Intracellular Aβ42 
accumulations and vascular Aβ deposits have been found in the parietal cortex 3 
months after STZ icv treatment (Salkovic-Petrisic et al., 2011, Knezovic et al., 2015). 
Starting from 6 months up to 9 months, both intra- and extracellular primitive 
plaque-like Aβ42 accumulations can be detected in the parietal cortex and 
subhippocampal thalamic region and to a lesser extent in the hippocampus (Knezovic 
et al., 2015). For hyperphosphorylated tau protein, AT8 immunoreactivity (tau 
protein phosphorylated at Ser202/Thr205 sites) was increased in a time-dependent 
manner, appearing first in neocortical regions 1 month after STZ icv treatment and 
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spreading to the hippocampal areas (Knezovic et al., 2015). After STZ icv 
administration, brain glucose/energy metabolism abnormalities have been found in 
all hippocampal subfields, such as decreased glucose utilization (Duelli et al., 1994) 
and reduced glycolytic key enzymes activity (Plaschke and Hoyer, 1993), diminished 
adenosine triphosphate (ATP) and creatine phosphate (Lannert and Hoyer, 1998) as 
well as decreased IR expression (Barilar et al., 2015).. Choline acetyltransferase 
(ChAT) activity in the hippocampus is shown to be decreased already 1 week 
after STZ icv treatment, which lasts at least until 3 weeks post-injections 
(Blokland and Jolles, 1993). Also these alterations of the cholinergic system in 
the STZ icv rat model resemble biochemical changes observed in Alzheimer's 
disease (Sharma and Gupta, 2001, Saxena et al., 2011). Most of Alzheimer-like 
alterations typical for AD patients were also shown to happen in the STZ icv treated 
rats as summarized in table 1. Moreover, in Fig.3 a timetable with brain metabolism 
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Table 1. Summany of the similarities between human sAD and the STZ icv rat model 
                                                                                                                                                                                          
 
Note: Summarized from (Salkovic-Petrisic et al., 2006, Grunblatt et al., 2007, Salkovic-Petrisic et 
al., 2009, Salkovic-Petrisic et al., 2011, Salkovic-Petrisic et al., 2013a).  
 
 
Fig.3. Timetable of pathological characteristics in STZ icv rats 
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In summary, the STZ rat model represents a feasible experimental approach to 
explore the underlying cellular and molecular mechanisms involved in the initial and 
late stages of sAD pathology. 
 
 
1.3 Adult neurogenesis  
The phenomenon of adult neurogenesis (AN), the generation of functional neurons 
in the adult brain, has been shown to be active not only in most of the animals 
tested, but also in humans (Altman and Das, 1965, Eriksson et al., 1998, Wiskott et 
al., 2006). Neural stem cells (NCSs) are responsible for the generation of new 
neurons and reside in two main locations in the adult mammalian brain: the 
subventricular zone (SVZ) of the lateral ventricle, and the subgranular zone (SGZ) of 
the dentate gyrus (DG) of the hippocampus (Fig.4) (Ming and Song, 2005, von Bohlen 
und Halbach, 2011). In other brain regions than the SVZ and the SGZ the birth of new 
neurons appears to be extremely limited in the adult mammalian. Only after 
pathological stimulation like brain insults, AN appears to occur in these other regions 
(Ming and Song, 2005). But even if we are always mentioning the generation of new 
neurons, it cannot be denied that the proliferation of NSCs also results in the 
production of a small number of astrocytes [1-13% ; (Malberg et al., 2000, van Praag 
et al., 2002, Schmitt et al., 2007)] and oligodendrocytes (Bribian et al., 2012).  
 




Fig.4. Neurogenic zones in the adult mouse brain  (Pozniak and Pleasure, 2006).  
Newborn cells are continually born throughout whole life in predominantly two regions of the 
brain: the subventricular zone (SVZ) of the lateral ventricle (LV), where newborn neurons migrate 
to the olfactory bulb via the rostral migratory stream (RMS); and the subgranular zone (SGZ) of 
the dentate gyrus (DG) of the hippocampus, where most of these newborn cells passing through 
several differentiation stage and finally become integrated into the local neuronal network as 
granule cells. Newly generated granule cells receive synaptic input from entorhinal cortex and 
extend axons along the mossy fibers tract that pass through the hilus and form synapses with 
pyramidal neurons from cornu ammonis (CA) section 3, another part of hippocampus.    
 
From a functional point of view, hippocampal AN plays an important role in several 
brain functions such as learning and memory processes (Aimone et al., 2010) and 
stress responses (Snyder et al., 2011). Some mutant mice with decreased SGZ 
neurogenesis have impaired performance on hippocampus-dependent learning tasks, 
such as methyl-CpG binding protein 1 (mbd1-/-) mice (Zhao et al., 2003), fibroblast 
growth factor receptor 1 (fgfr1flox/-) mice (Zhao et al., 2007), neurotrophin-3 (NT-3flox/-) 
mice (Shimazu et al., 2006). Using different models in which AN was chemically 
[systemic treatment with antimitotic drugs like methylazoxymethanol acetate (MAM)] 
(Shors et al., 2001), physically (x-ray irradiation) (Saxe et al., 2006) or genetically 
[ablation of glial fibrillary acidic protein (GFAP)-positive neural progenitor cells] (Saxe 
et al., 2006) inhibited, impaired hippocampus-dependent learning and memory 
ability has been found. Besides other possible influcences different performances in 
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the behavioral task could be related to the different age of mice analysed. For 
example, Raber and colleagues found that 2 months old mice with x-ray radiation in 
the hippocampus exhibited impaired spatial learning and memory in the Barnes 
maze but not in the Morris water maze (Raber et al., 2004). However, the study from 
Rola and colleague showed that 21-day-old mice which received x-ray radiation 
showed impaired spatial learning and memory performance in the Morris water 
maze but not in the Barnes maze (Rola et al., 2004). Additionally, the maturation 
stage of AN on learning and memory is revealed by Deng and coworkers that mice 
with a reduced population of adult-born DG neurons at the immature stage were 
deficient in forming robust, long-term spatial memory and displayed impaired 
performance in extinction tasks (Deng et al., 2009). The cascade of events linking the 
birth of new neurons to learning processes is unclear, as is the way in which new 
neurons are integrated into and/or removed from behaviorally relevant hippocampal 
neural networks. First insights into these issues were gained from a study of Dupret 
and co-workers on the effect of spatial learning in the Morris water maze on cell 
birth and death in the rodent hippocampus. This work revealed that spatial learning 
is associated with three different events: learning promoted survival of relatively 
mature neurons, apoptosis of more immature cells, and finally, proliferation of neural 
precursors (Dupret et al., 2007).  
 
Recently, more and more studies of AN in memory formation have been focused on a 
specific function - pattern separation, which is a process of making similar 
representations more distinct (Snyder and Cameron, 2012). Both, mice with ablated 
neurogenesis due to focal x-ray radiation and mice with targeted lentiviral expression 
of dnWnt show impaired spatial discrimination for similar but not distinct spatial 
locations (Clelland et al., 2009). Until now, we only know little about the function of 
AN, so that future studies should highlight the precise functional relevance of newly 
born neurons.  
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1.3.1 Different stages of AN  
AN is a complex multi-stage process during which proliferating stem cells as well as 
the differentiation and migration of their newborn progeny happens (Ming and Song, 
2005). From which cells NSCs originate is still on debate and several cell types have 
been suggested to be the real NSCs including migratory neuroblasts with large 
nucleus co-expressing β–tubulin (Type A) (Bonfanti and Theodosis, 1994, Lois et al., 
1996), astrocytes expressing GFAP (Type B) (Doetsch et al., 1999), transit amplifying 
cells (Type C), and multiciliated ependymal cells (Type D) (Johansson et al., 1999). 
The most popular view is that astrocyte-like cells which co-express GFAP are the real 
neural stem cells (Alvarez-Buylla and Lim, 2004). In the SGZ, several researchers 
suggested to divide AN in five stages which begin with a subset GFAP positive cells 
(Fig.5) (Seri et al., 2001). These cells, their cell bodies locate in the SGZ and have 
radial processes going through the granule cell layer (GCL) and short processes 
extend along the border of the GCL and hilus (Ming and Song, 2005). In the end of 
this stage these cells give rise to transit amplifying cells, and then get into stage 2 
when transit amplifying cells differentiate into immature neurons during about 4 
days (Ming and Song, 2005). Newly generated neurons migrate only a short distance 
to the inner GCL to become granule neurons (Ming and Song, 2005). In stage 4, 
immature neurons extend their axonal projections along mossy fiber pathways to the 
CA3 pyramidal cell layer and their dendrites toward the molecular layer (ML) (Ming 
and Song, 2005). Then the immature neurons receive inputs e.g.  from the 
entorhinal cortex and send output to the CA3 region and form connections with CA3 
pyramidal cells (Ming and Song, 2005). It takes about 2 months for the maturation of 
newborn cells in the hippocampus (Piatti et al., 2011). 
 




Fig.5. Different stages of AN in dentate gyrus (Ming and Song, 2005) 
Adult neurogenesis in dentate gyrus is suggested to be divided into five stages. Stage 1 (blue). 
Proliferation:  the cell bodies of neural stem cells (NSCs) locate in the SGZ and have radial 
processes going through the granule cell layer (GCL) and short processes extend along the border 
of the GCL and hilus. In this stage, these cells could be stained with GFAP antibody and nestin 
antibody and regulated by basic fibroblast growth factor (FGF-2), epidermal growth factor (EGF), 
sonic hedgehog (Shh). Stage 1 lasts about 25h and in the end of stage 1 NSCs give rise to transit 
amplifying cells. Stage 2 (green). Fate specification: transit amplifying cells differentiate into 
immature neurons during about 4 days. In this stage, newborn cells start to express markers like 
polysialylated-neural cell adhesion molecule (PSA-NCAM) and doublecortin (DCX). Stage 3 
(yellow). Migration: Immature neurons migrate a short distance into the inner granule cell layer. 
Stage 4 (orange). Axon/dendrite targeting: immature neurons extend their axonal projections 
along mossy fiber pathways to pyramidal cells of the cornu ammonis region 3 (CA3) and their 
dendrites toward the molecular layer (ML). In this stage, cells express calretinin for a short time 
and start to express the neuron marker neuronal nuclei (NeuN). This stage takes about 4-10 days. 
Stage 5 (purple). Synaptic integration: newborn cells receive inputs e.g. from the entorhinal 
cortex and send output to the CA3 region and form connections with CA3 pyramidal cells. In this 
stage, the cells start to express calbindin and form action potentials. 
 
1.3.2 The phenomenon of adult neurogenesis is tightly regulated 
AN in the hippocampus is a dynamic process that could be regulated at different 
stages by both, intrinsic and extrinsic factors (Fig.5) (Ming and Song, 2005). Aging is 
the most important factor influencing AN, as it declines rapidly with aging (Kuhn et 
al., 1996). Chronic stress elicits a negative regulation of AN (Gould et al., 1997) while 
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acute stress enhances hippocampal AN (Kirby et al., 2013). On the other hand, 
increased environmental complexity (Kempermann et al., 1997) and physical activity 
(Gould et al., 1999, van Praag et al., 1999) leads to an increase of AN. Most brain 
injuries lead to increased NSC proliferation in the SGZ and induce newborn cells to 
migrate to the injury site, such as ischemic brain injury (Arvidsson et al., 2002), 
mechanical lesions (Gould and Tanapat, 1997) and prolonged seizures (Parent and 
Lowenstein, 1997).  
 
Intrinsic hormones, for example, adrenal steroids may contribute to the 
aging-associated AN decline (Cameron and Gould, 1994). Other hormones, including 
estrogen (Tanapat et al., 1999), thyroid hormone (Desouza et al., 2005), and 
progesterone (Shingo et al., 2003) also regulate AN. Beside hormones, many 
neurotransmitters were also found to influence AN, including neurotransmitters like 
dopamine, serotonin (5-hydroxytryptamine, 5-HT), acetylcholine, 
gamma-Aminobutyric acid (GABA), glutamate, and the gaseous neurotransmitter 
nitric oxide (NO) (Ming and Song, 2005). Experimental depletion of dopamine in 
rodents decreased the cell proliferation and survival of NSCs in SGZ (Hoglinger et al., 
2004) and a postmortem study showed that number of NSCs was reduced in SGZ in 
Parkinson disease patients (Borta and Hoglinger, 2007). An in vitro study found that 
dopamine increased the number of NSCs via D1-like but not D2-like receptor as 
D1-like receptor antagonist R-SCH23390 but not D2-like receptor antagonist sulpiride 
could attenuate dopamine induced increase of NSCs (Takamura et al., 2014). 
Interestingly, another dopamine receptor antagonist haloperidol could increase cell 
proliferation in a dopamine D2 receptor-dependent manner (Kippin et al., 2005). 
5-HT is shown to have a stimulating effect on AN in the DG (Brezun and Daszuta, 
2000) and mice lacking the 5-HT transporter which exhibit higher 5-HT levels in the 
synaptic cleft also have higher levels of hippocampal AN (Schmitt et al., 2007, 
Karabeg et al., 2013). Acetylcholine positively influences stem cell proliferation in the 
SGZ, whereas cholinergic pathology per se may have a detrimental influence on 
neurogenesis (Perry et al., 2012). In SVZ, ChAT expressing neurons have been 
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found to exhibit an activity-dependent control of NSCs` proliferation 
(Paez-Gonzalez et al., 2014). Glutamate promotes proliferation of SVZ-derived 
progenitor cells in vitro (Brazel et al., 2005), whereas in the DG activation of 
N-methyl-D-aspartate receptor (NMDA receptor), a glutamate receptor, results 
in diminished hippocampal AN and treatment with NMDA receptor antagonists 
increases the birth of neurons (Cameron et al., 1995). GABA released by 
parvalbumin expressing interneurons depolarizes progenitor cells and inhibits 
proliferation via GABA-receptor activation (Song et al., 2012). Under physiological 
conditions, NO inhibits stem cell proliferation (Packer et al., 2003), but after focal 
cerebral ischemia the expression of inducible nitric oxide synthase (iNOS) which 
catalyzes the production of NO could stimulate AN (Zhu et al., 2003).  
 
Growth factors also play an important role in the regulation of AN, such as fibroblast 
growth factor-2 (FGF-2), epidermal growth factor (EGF) (Kuhn et al., 1997), 
brain-derived neurotrophic factor (BDNF) (Waterhouse et al., 2012), vascular 
endothelial growth factor (VEGF) (Cao et al., 2004), insulin (Arsenijevic et al., 2001) 
and IGF-1 (Aberg et al., 2000). Several drugs regulate AN including antidepressants 
(Malberg et al., 2000) and Lithium (Chen et al., 2000) (up-regulation), opiates (Eisch 
et al., 2000) and methamphetamine (Teuchert-Noodt et al., 2000) (down-regulation). 
 
1.3.3 Energy metabolism influence proliferation and differentiation of neural stem 
cells  
That energy metabolism, especially glucose metabolism, could have an influence on 
AN is substantiated by microarray studies performed by Geschwind et al. (Geschwind 
et al., 2001) and Ivanova et al. (Ivanova et al., 2002). They showed that proliferation 
of NSCs and the transition from a newborn undifferentiated cell to a differentiated 
neuron, astrocyte, or oligodendrocyte is accompanied by many changes of the 
expression of metabolism related genes such as IGF binding protein 3, cytochome c 
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oxidase (Geschwind et al., 2001), enolase 1, acetyl-coenzyme A synthetase 1 and 
pyruvate dehydrogenase E1 alpha subunit (Karsten et al., 2003).  
 
The Insulin/IGF-1 signaling pathway is central in coordinating energy taking and 
expenditure (Rafalski and Brunet, 2011). Although IGF-1 mRNA was detected in all 
regions of the neonatal brain, there is considerable regional variation in the level of 
expression with highest expression levels in regions where neurogenesis persists 
after birth such as the hippocampus and the subventricular zone (Bartlett et al., 
1991). The association of AN and insulin signaling pathways is substantiated by the 
fact that adult NSCs express the IGF-1 receptor (Aberg et al., 2003). Both, insulin and 
IGF-1, have mitogenic effects (Hofmann et al., 1989). For insulin, it is shown that it 
promotes the function of FGF 2 and activates stem cell proliferation 
(Arsenijevic et al., 2001). Han and colleagues found that high insulin concentration 
could induce NSCs differentiation into neurons (Han et al., 2008). For IGF-1, Aberg 
and coworkers found that high doses could promote NSCs proliferation and a low 
IGF-1 dose gives an instructive signal to cultured NSCs to become neurons (Aberg et 
al., 2003). That is why it is not surprising that the size of the brain in mice 
overexpressing IGF-1 are 55% larger than those of controls (Carson et al., 1993). 
Interestingly, IGF-1 could stimulate NSCs differentiation into oligodendrocytes in an 
animal model (Ye et al., 1995) and in cell culture (Hsieh et al., 2004).  
 
Several signaling pathways downstream of the insulin/IGF-1 receptor may be 
involved in the proliferation of NSCs and the differentiation of newborn cells (Fig.6). 
IGF-1 is known to promote cell proliferation by activating the phosphoinositide 
3-kinase/Protein kinase B (PKB, also called Akt) (PI3K/Akt) pathway (Blakesley et al., 
1996). IGF-1 enhances the phosphorylation of Akt in NSCs and using 
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, an inhibitor for PI3K, could 
inhibit the IGF-I-induced survival of NSCs (Kalluri et al., 2007). Mice with 
brain-specific deletion of the pten gene, a negative regulator for PI-3K/Akt signaling, 
exhibit an increased number of embryonic NSCs (Groszer et al., 2001). Furthermore, 
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PI3K/Akt signaling also is shown to regulate the differentiation of neuroal precursor 
cells by IGF-1 (Otaegi et al., 2006). The PI3K-Akt-FoxO (Forkhead box protein O) 
signaling pathway, a branch of PI3K/Akt signaling, plays a prominent role in NSC 
proliferation and renewal. FoxO-deficient mice show initial increased brain size and 
proliferation of neural progenitor cells during early postnatal life, followed by 
precocious significant decline in the NSC pool and accompanying neurogenesis in 
adult brains (Paik et al., 2009). PI3K-Akt-mTOR signaling, another branch of PI3K/Akt 
pathway, may also play a role in the regulation of NSCs as inhibition of mTOR 
(mammalian target of rapamycin)-containing complexes by rapamycin reverses 
insulin-dependent enhancement of neurogenesis (Han et al., 2008). 
  
Fig.6. Potential pathways by which insulin/IGF signalling can regulate neurogenesis [modified 
from (Bateman and McNeill, 2006)] 
Abbreviation: AKT: also called PKB (Protein kinase B); FOXO: Forkhead box protein O; Grb2: 
Growth factor receptor-bound protein 2; IR: Insulin receptor; IGF-1R: Insulin-like growth factor-1 
receptor; IRS: Insulin receptor substrate; mSOS: mammalian homologues of son of sevenless; 
MAPK: Mitogen-activated protein kinase; mTOR: mammalian target of rapamycin; PI3K: 
phosphoinositide 3-kinase; PTEN: phosphatase and tension homologue; Ras: Rat sarcoma; shc: 
Src homology 2 domain containing transforming protein.  
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1.3.4 Different methods to analyze adult neurogenesis 
In vivo studies commonly use thymidine analogs which could incorporate DNA of 
dividing cells during the S-phase of the cell cycle to monitor cell proliferation (Taupin, 
2007). Decades ago, [3H]-thymidine autoradiography had been used for AN studies 
(Sidman et al., 1959, Kaplan and Hinds, 1977), but now BrdU 
(5-bromo-2′-deoxyuridine) has replaced it because of many advantages as it can be 
quickly detected via immunohistochemistry and combined with other antibodies it 
can be used to perform immunofluorescence double stainings (Gratzner et al., 1975, 
Gratzner, 1982, Nowakowski et al., 1989, Magavi and Macklis, 2008). Since BrdU can 
cross the blood-brain barrier (BBB), it may be delivered to the brain by 
intracerebro-ventricular (icv), intraperitoneal (ip), intravenous (iv) injection, or even 
orally (Taupin, 2007). Different BrdU labeling paradigms are used to determine cell 
proliferation, migration, maturation as well as the fate of newborn cells by varying 
the period between the BrdU injection(s) and the sacrifice of the animals (Miller and 
Nowakowski, 1988, Taupin, 2007). A short-term survival of animals (between 1 and 3 
hours) after BrdU application could be used for the detection of NSCs proliferation 
(Palmer et al., 2000). The fate of newly generated neuronal cells and maturation 
stages can be determined with a somehow long-term survival of the animals after 
BrdU application up to ca. 4 weeks (Kuhn et al., 1996, Duman et al., 2001, Taupin, 
2007). Via immunofluorescence double stainings and the use of antibodies detecting 
BrdU and other cell-type specific marker [such as neuronal nucleus (NeuN), 
adenomatous polyposis coli (APC) as well as GFAP] the cellular fate of a newborn cell 
can be verified.  
 
Besides BrdU incorporation, staining with different markers has been proposed to 
assay different stages of AN. Proliferating NSCs express proteins such as Ki-Kiel67 
(Ki67), mini-chromosome maintenance proteins 2 (MCM2). MCM2 is one of the 
highly conserved mini-chromosome maintenance proteins that are involved in the 
initiation of eukaryotic genome replication and is commonly used as a marker for 
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proliferating cells (Kneissl et al., 2003). Newborn cells with a neuronal fate express 
markers such as neurogenic differentiation (NeuroD), doublecortin (DCX) and 
neuronal nucleus (NeuN). NeuroD, a basic helix-loop-helix (bHLH) transcription factor, 
is excusively expressed in mitotic neuroblasts (Miyata et al., 1999). The microtubule 
binding protein DCX labels mitotic active neuroblasts as well as postmitotic immature 
neurons, which extend their dendrites into the molecular layer of the DG (Brown et 
al., 2003). NeuN is a neuronal nuclear antigen that is commonly used as a marker for 
mature neurons (Mullen et al., 1992).  
 
Living organisms are extremely complex systems and it is hard to explore their basic 
biological functions. In order to simplify research work, in vitro methods have been 
established for studying proliferation and differentiation signaling pathways in AN. 
Numerous investigators have isolated NSCs from the mouse and rat neurogenic brain 
regions and used a variety of mitogenic growth factors to stimulate cell proliferation, 
such as EGF and FGF-2 (Gage et al., 1995, Gritti et al., 1996, Svendsen et al., 1997, 
Gritti et al., 1999). Under different conditions, NSCs grow as monolayers or as 
so-called neurospheres. When mouse CNS-derived NSCs were plated on uncoated 
plates and cultured in medium containing EGF, FGF-2 and heparin, the cells form a 
monolayer of cells (Ray and Gage, 2006). However, if the NSCs were exposed to EGF 
or FGF-2 alone or EGF+FGF-2 (together) without heparin, they form neurospheres 
(Ray and Gage, 2006). For rats, in the presence of FGF-2, EGF and heparin, cells 
proliferate within neurospheres, but if these cells were plated on uncoated plates in 
serum and then let them grow in N2+FGF-2 medium, they will form a monolayer (Ray 
and Gage, 2006). NSCs proliferation can be detected by counting the number of 
neurospheres, measuring the size of neurospheres or analyzing the absolute number 
of proliferating cells by the incorporation of BrdU with subsequent 
BrdU-Immunohistochemistry (Stafford et al., 2007, Karkkainen et al., 2014). Different 
markers could be used like in in in vitro studies to detect the fate of NSCs, such as 
neuron-specific class III beta-tubulin (Tuj-1) and GFAP (Karkkainen et al., 2014). 
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1.4 Adult neurogenesis in Alzheimer’s disease 
There is a big controversy in literature regarding the possible involvement of AN in 
AD etiopathology (Table 2). The study of Jin and coworkers demonstrated increased 
AN (marked by DCX) in hippocampus of AD patients (Jin et al., 2004). However, 
Boekhorn and coworkers couldn`t detect significant changes in cell proliferation 
(marked by Ki67) in the human DG of AD brains compared to controls (Boekhoorn et 
al., 2006).  
 
Table 2. Neurogenesis in human postmortem tissues and in animal models of AD 
 
 
The tissue samples used in the Jin et. al. study were from senile AD patients, which 
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points to increased AN in patients with sAD compared to normal group (Jin et al., 
2004). However, the samples that showed no significant changes in AN were from 
presenile AD (fAD) cases (Boekhoorn et al., 2006). The controversy of AN changes in 
above mentioned studies may due to different types of disease analysed, fAD and 
sAD.  
 
Using animal models for studying AN is an alternative. Most animal models used for 
studying AN are based on the amyloid cascade hypothesis by promoting Aβ plaques 
production in the brain. However, AN studies using transgenic mice which 
overexpress hAPP and/or PS1/2 could also not answer this question of a possible 
involvement of AN in the etiopathogenesis of AD (Marlatt and Lucassen, 2010, Mu 
and Gage, 2011). Just to give some examples: Some research groups revealed 
impaired AN, e.g. in the TCRND8 (TG) mice carrying the human APP 695 (hAPP) 
including the “Swedish” and “Indiana” mutations (hAPPSw,Ind mice) controlled by 
the Syrian hamster prion promoter (Herring et al., 2009), whereas other studies 
using APP23 mice with Swedish mutation (Ermini et al., 2008) as well as 
PDGF-APPSw,Ind mice, which also express the Swedish and Indiana APP mutations 
but under the control of a PDGF promotor (Jin, et al., 2004a) revealed increased AN 
in the hippocampus.  
 
Many molecules involved in Aβ production and metabolism have been found to be 
linked to AN (Mu and Gage, 2011). Cleavage of APP by β- and γ-secretase as 
amyloidogenic pathway yields the APP intracellular domain (AICD) fragment in 
addition to Aβ, but the activity of α- and γ-secretase as a part of the 
non-amyloidogenic pathway generates the soluble fragment of APP (sAPPα) (Mu and 
Gage, 2011). Both, AICD and sAPPα, could influence AN. AICD expression decreases 
hippocampal progenitor cell proliferation and survival (Ghosal et al., 2010) and 
sAPPα protects neurons and AN (Han et al., 2005). Mutations of PS1 which is a 
component of γ-secretase decrease the production of new neurons (Wen et al., 
2004). For Aβ itself, the role in regulating AN is complex. Low concentrations of 
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monomeric Aβ exerts a neurotrophic function on undifferentiated hippocampal 
neurons (Yankner et al., 1990) and stimulates primary neural progenitor cells` 
proliferation (Chen and Dong, 2009). A low micromolar concentration of oligomeric 
Aβ increased the proliferation of adult NSCs and high concentration was shown to be 
neurotoxic (Heo et al., 2007).  
 
 
1.5 Hippocampus functional dissociation 
The hippocampus, one of the neurogenic brain region in the adult brain, is a 
heterogeneous brain area, extends dorso-ventrally from the septal nuclei of the basal 
forebrain to the temporal lobe (Fig.7) (Tanti and Belzung, 2013). Along the 
septo-temporal (also called dorso-ventral, anterior-posterior or rostro-caudal) axis, 
the hippocampus is shown to have different functions (Tanti and Belzung, 2013, 
Strange et al., 2014). It’s important to note that septal hippocampus in rodents 
represents the posterior hippocampus in humans and rodent temporal hippocampus 
represents the anterior hippocampus in humans (Fig.7) (Strange et al., 2014). The 
septal part of the hippocampus primarily plays a role in spatial learning based on the 
following evidences. Moser and colleagues found that septal hippocampal lesions 
consistently impaired spatial learning in a Morris water maze and the degree of 
impairment correlated with the lesion volume (Moser et al., 1993). In contrast, 
lesions of the temporal hippocampus spared both the rate and the precision of 
learning (Moser et al., 1993). The study of Vann and colleagues suggests that 
increased c-fos activation, an indirect marker of neuronal activity, was found in both 
septal and temporal hippocampus, but relative increase was significantly greater in 
the septal part after performing spatial tasks (Vann et al., 2000). The temporal 
hippocampus is more integrated into networks dealing with stress and 
emotion (Henke, 1990, Fanselow and Dong, 2010) and temporal hippocampal 
but not septal hippocampal lesions enhanced cold/restraint stress ulcers 
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(Henke, 1990). Temporal hippocampus seems to be preferentially involved in 
anxiety-like behavior studied in various tests like tone fear conditioning 
(Maren and Holt, 2004), social interaction test (McHugh et al., 2004), as well 
as contextual fear conditioning (Maren and Holt, 2004). Using brain tissue 
oxygen amperometry, McHugh et al. also confirm that septal hippocampus is 
associated with spatial processing and temporal hippocampus is associated 
with anxiety-related behavior (McHugh et al., 2011). These difference may due 
to the fact that septal hippocampus primarily receives afferents from the 
retrosplenial and from the anterior cingulate cortex (Cenquizca and Swanson, 
2007), however, the temporal hippocampus receives inputs from areas linked 
with olfactory processing (Cenquizca and Swanson, 2007) and has reciprocal 
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Fig.7. Schematic view of the orientation of the hippocampal axis in rats, macaque monkeys and 
humans (Strange et al., 2014) 
The hippocampus is a heterogeneous brain area, extends dorso-ventrally from the septal nuclei 
of the basal forebrain to the temporal lobe. Septal hippocampus (also called dorsal hippocampus) 
in rodents represents the posterior hippocampus in humans and monkeys, and rodent temporal 
hippocampus (also called ventral hippocampus) represents the anterior hippocampus in humans 
and monkeys. 
 
Interestingly, the characteristics of AN are also found to be different in the septal and 
temporal hippocampus (Piatti et al., 2011). The DG in septal hippocampus displays 
higher levels of basal network activity and faster rates of newborn neuron 
maturation than the temporal region (Piatti et al., 2011). 
 
In recent years AD researchers started to analyze septal and temporal 
hippocampus separately (Fuster-Matanzo et al., 2011, Yiu et al., 2011). 
Fuster-Matanzo and coworkers demonstrated that increased 
neurodegeneration in consequence of GSK3ß overexpression in mice was 
detected exclusively in septal hippocampus (Fuster-Matanzo et al., 2011). In 
addition, locally and acutely increasing cyclic adenosine monophosphate 
(cAMP) response element-binding protein (CREB) function in the CA1 of septal 
hippocampus in TgCRND8 mice was sufficient to restore function in neuronal 
structure, network activity as well as learning and memory (Yiu et al., 2011). 
 
1.6 Objective of the thesis 
As STZ icv treated rats mirror an insulin resistant brain state and exhibit cognitive 
deficits resembling memory deficits in AD patients, they are proposed to be an 
animal model for sAD. Until now only very few studies have been reported on AN in 
STZ icv rat model and they analyzed AN exclusively in brains up to 3 weeks following 
STZ icv administration (Arabpoor et al., 2012, Qu et al., 2012). In this study, our goal 
was to examine short-term (1 month) and long-term (3 months) effects of STZ icv 
treatment on adult hippocampal neurogenesis. We performed a quantitative 
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immunohistochemistry study and double/triple immunofluorescence stainings using 
antibodies detecting different AN stages, e.g. proliferation of stem cells, 
differentiation and survival of adult-generated neurons. As it is suggested that the 
hippocampus is functionally different along its septo-temporal axis, we analyzed the 
septal and temporal part of the hippocampus separately.  
 
In order to explore the mechanism of STZ effects on the proliferation of stem cells 
and the differentiation of newborn cells, I performed in vitro studies using cultured 
primary adult rat NSCs. The number and size of neurospheres in the presence of 
different concentrations of STZ as well as the migration of newborn differentiating 
cells was evaluated. Moreover, double immunofluorescence staining allowed us to 
detect whether STZ influences the differentiation fate of newborn cells. For the 
investigation of possible expression changes of molecules related to brain 
metabolism and/or especially to IR signaling pathways (such as GLUT1 and 3, IR, 
IGF-1) in consequence of STZ treatment quantitative real time polymerase chain 
reaction (qRT-PCR) for the detection of specific mRNAs was performed followed by 
immunofluorescence stainings for the detection of interesting proteins.  
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2. Material and Methods  
2.1 Material 
2.1.1 Brain tissue  
Brain tissue of STZ icv treated rats – in vivo study. STZ icv treatment of rats for our in 
vivo study was performed by the research group of our collaboration partner Prof. 
Salkovic-Petrisic (Department of Pharmacology, School of Medicine, University of 
Zagreb, Zagreb, Croatia). Dissected and subsequently for 72 h in 4% PFA (dissolved in 
PBS, pH 7.5) fixed brains were then sent to the laboratory of the Department of 
Psychiatry, Psychosomatics and Psychotherapy of the University of Wuerzburg, 
Wuerzburg.  
 
In brief, the STZ icv rat model was produced as described in the following: A total of 
36 three- and five-month old male Wistar rats weighing 280–330 g were used for this 
study (Department of Pharmacology, School of Medicine, University of Zagreb, 
Zagreb, Croatia). Animals were kept in standardized cages (2-3 animals per cage) 
maintained under a 12/12h light/dark circle and provided with standard food pellets 
and water ad libitum. Experiments were carried out under the guidance of the 
Principles of Laboratory Animal care (NIH Publication No. 86-23, revised in 1985), 
conformed to Directive 2010/63/EU, and in line with the actual national law, the 
Animal Protection Act (NN135/06). Experiments were approved by the Ethical 
Committee of the University of Zagreb School of Medicine and the national 
regulatory body responsible for issuing ethical approval, Croatian Ministry of 
Agriculture (licence No. UP/I-322-01/11-01/100 to MSP for research approved by 
Croatian Ministry of Science, Education and Sport, project 108-1080003-0020 to 
MSP).  
 
STZ icv injections were performed according to the procedure described first by 
Noble et al (Noble et al., 1967) and applied afterwards by Salkovic-Petrisic and 
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co-workers (Salkovic et al., 1995, Grunblatt et al., 2007, Salkovic-Petrisic et al., 2011, 
Salkovic-Petrisic et al., 2013b).  Briefly, rats were given general anaesthesia 
[chloralhydrate, 300 mg/kg ip)], and STZ (1.5 mg/kg, dissolved in 0.05M citrate buffer 
pH 4.5) was injected into the left and right lateral ventricle (2 μl per ventricle) of the 
rat brain. STZ treatment was repeated on the 3rd day after the first injection. STZ was 
dissolved in 0.05 M citrate buffer, pH 4.5. Control animals received icv an equal 
volume of vehicle (citrate buffer). Additionally, a group of control animals was left 
intact without any icv treatment. Experimental rats were randomly divided into five 
experimental groups (see Fig. 8) with six to eight animals per group: Group 1 
(control), intact rats without any icv treatment; Group 2 (vehicle 1 month), vehicle 
icv-treated rats at the age of 5 months; Group 3 (STZ 1 month), STZ icv-treated rats at 
the age of 5 months; Group 4 (vehicle 3 months), vehicle icv-treated rats at the age 
of 3 months; Group 5 (STZ 3 months), STZ icv-treated rats at the age of 3 months. 
Irrespective of treatment, all animals were sacrificed at the age of 6 months. 
 
To label cells undergoing cell division, they used the exogenous marker 
5-bromo-2`-deoxyuridine (BrdU), a thymidine analogue which incorporates into DNA 
during synthesis (Lehner et al., 2011). Each rat received ip injections of 50 mg/kg 
body weight BrdU (Roche Diagnostics, Mannheim, Germany; dissolved in PBS) and 
BrdU was applied once daily on 7 consecutive days. Rats were sacrificed 27 days after 
the first ip BrdU injection. The experimental timeline is provided in Fig.8. 
 
 




Fig.8. Experimental design  
Rats were randomly divided into five groups (n=6-8 per group): two groups were STZ icv treated 
(STZ 1 month/STZ 3 months), two groups were vehicle icv treated (Vehicle 1 month/Vehicle 3 
months) and one group was the absolute control group without any icv treatment. Vehicle/STZ 1 
month: rats which received vehicle or STZ icv treatment at the age of 5 months. Vehicle/STZ 3 
months: rats which received vehicle or STZ icv treatment at the age of 3 months. Rats were given 
general anesthesia (intraperitoneal (ip) injections of chloralhydrate 300 mg/kg body weight), and 
then STZ (1.5 mg/kg body weight) or vehicle (0.05 M citrate buffer, pH 4.5) was injected into the 
left and right lateral ventricle of the rat brain (indicated by a red arrow). STZ or vehicle treatment 
was repeated on the 3rd day after the first injection. Moreover, each rat received ip injections of 
50 mg/kg body weight BrdU, which was applied once daily on seven consecutive days (indicated 
by an expanded black arrow). Rats were sacrificed 27 days after the first ip BrdU injection. 
Irrespective of treatment all animals were sacrificed with 6 months of age.  
 
Brain tissue for the in vitro study. The 2 months old Wistar rats were bought from 
Charles River Laboratories (Sulzfeld, Germany). About 40 rats were used during our in 
vitro study. Animals were anesthetized by isoflurane and sacrificed by decapitation. 
Protocols fulfill the requirements of German law. 
 
2.1.2 Antibodies  
Antibodies Company Dilution 
Goat anti-DCX Santa Cruz 1:500 
Goat anti-MCM2 Santa Cruz 1:1000 
Goat anti-NeuroD Santa Cruz 1:500 
Mouse anti-APC Calbiochem 1:200 
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Mouse anti-Iba-1 Wako 1:1000 
Mouse anti-Tuj-1 Abcam 1:250 
Mouse anti-NeuN Chemicon 1:250 
Rat anti-BrdU Serotec 1:300  





Rabbit anti-Nestin Abcam 1:250 
Alexa 350 donkey 
anti-rabbit antibody 
Life technologies 1:500 
Alexa 488 donkey 
anti-rat  antibody  
Life technologies 1:500 
Alexa 555 donkey 
anti-mouse  antibody 
Life technologies 1:500 
Biotinylated anti-goat 
IgGs antibody  
Vector laboratories 1:1000 
Biotinylated anti-mouse 
IgGs antibody 
Vector laboratories 1:1000 
 
2.1.3 Kits 
Kits Source Application 
3,3’-Diaminobenzidine 
(DAB) substrate kit 
Roche IHC 
First strand cDNA 
synthesis kit 
With the following 
component: 
a: 5 × iScript reaction mix 
b: iScript reverse 
transcriptase 
c: Nuclease-free water 
Bio-Rad Real time PCR 
NeuroCult™ NS-A 
Differentiation Kit (Rat) 
With the following 
Stemcell Cell culture 




a: Neurocult NS-A 
differentiation supplement 
b: Neurocult NS-A basal 
medium 
NeuroCult™ NS-A 
Proliferation Kit (Rat) 
With the following 
component: 
a: Neurocult NS-A 
proliferation supplement 
b: Neurocult NS-A basal 
medium 
Stemcell Cell culture 
Papain Dissociation 
System 
With the following 
component: 
a: Earle's Balanced Salt 
Solution (EBSS) 
b: Papain 
c: Deoxyribonuclease I 
(Dnase I) 
d: Ovomucoid protease 
inhibitor with bovine 
serum albumin 
Worthington Cell culture 
Qiagen RNeasy Kit Qiagen Real time PCR 
SYBR Select Master Mix 
for CFX 
Thermo Fisher Scientific Real time PCR 
VECTASTAIN Elite ABC Kit Vector laboratories IHC 
 
2.1.4 Primers 
Primer Sequence Manufacturer Source 
GAPDH 
forward 




5’- gctaagcagttggtggtgca-3’ Metabion (Bonefeld et al., 
2008) 

















5’-tccaaaccaaagacctgagc-3’ Metabion (Weisova et al., 
2009) 
IR forward  5’-gctgtgtaaacttcagcttctgcc-3’ Metabion (Nakazawa et al., 
2005) 




5’-agggcgtagttgtagaagagtttcc-3’ Metabion (Steen et al., 2005) 
IGF1 
reverse 
5’-tacttgctgctgttccgagtgg-3’ Metabion (Steen et al., 2005) 
 
 
2.1.5 Chemicals, reagents and solutions 
Chemical/reagents Source Application 










Roche Indicates DNA synthesis 
and therefore 
proliferative events 
Basic fibroblast growth factor 
(FGF-b) 
Peprotech Cell culture 
Bovine serum albumin (BSA) Sigma IHC/ICC 
Dimethylformamide (DMF)  Molecular Probes 
 
Cell culture  






Gibco Cell culture 
Epidermal growth factor (EGF) Peprotech Cell culture 
Ethylenglycol Sigma IHC 
Fluoro mount Dako IHC/ICC: mounting 
medium 
Formamid Sigma IHC 
Glucose Sigma Cell culture 
Glycerin Applichem IHC 
H3BO3 Sigma IHC/ICC 
HCl Applichem IHC/ICC: adjust PH/break 
DNA double helix 
Hydrogen peroxide Sigma IHC: blockade of 
endogenous peroxidase 
KCl Sigma Buffer/solution 
preparation 
KH2PO4 Sigma Buffer/solution 
preparation 
Laminin Sigma Coat coverslips 
Isoflurane Forene For anesthesia 
NaCl Sigma Buffer/solution 
preparation 
NaH2PO4 Sigma Buffer/solution 
preparation 
Na2HPO4 Sigma Buffer/solution 
preparation 
NaOH Applichem Adjust PH 
Neutral Protease (Dispase) Worthington Cell culture 
Normal goat serum Vector IHC/ICC 
Normal horse serum Vector IHC/ICC 
Paraformaldehyde (PFA) Sigma Fixation of tissue/ cells 
Penicillin/Streptomycin Life technologies Cell culture 
Poly-L-Ornithine Sigma Coat coverslips 
Tris Sigma IHC/ICC 
Tris-EDTA (TE) buffer solution Sigma Real time PCR 
Triton X-100 Sigma IHC/ICC 
Vitro Clud R.Langenbrinck IHC: mounting medium  
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2.1.6 Buffer and media 
Buffer/medium Source Application 
0.1 M borate buffer Dissolve 3.09 g of boric acid 
(H3BO3) in 500 mL of water. The pH 
of the final solution will be 8.5 
IHC 
0.1 M phosphate 
buffer (PB) 
Add 3.1 g of NaH2PO4•H2O and 
10.9 g of Na2HPO4 (anhydrous) to 
distilled H2O to make a volume of 1 
L. The pH of the final solution will 
be 7.4. This buffer can be stored 





buffered saline (PBS) 
Dissolve the following in 800 ml 
distilled H2O: 8 g of NaCl; 0.2 g of 
KCl; 1.44 g of Na2HPO4; 0.24 g of 
KH2PO4. Adjust pH to 7.4. Then 




1x Tris buffered 
saline (TBS) 
0.15 M NaCl and 0.1 M Tris-HCl, pH 
7.5 
IHC/ICC 
4% PFA Pour 40 g PFA into a flask+500 ml 
of 1x PBS, and begin to stir. Place a 
thermometer into the solution to 
obtain continuous readings of 
temperature in the solution. 
Gradually start heating, but do not 
allow temperature to rise above 
60°C. After solutions cleared up, 
add the remaining 500 ml 1x PBS 
PBS solution. Then filter the 
solution and adjust the pH of 
filtered solution to 7.5 
Fixation of cultured 
cells and tissue 
Blocking buffer I  5% normal goat (or horse) serum, 
0.25% Triton X-100 and 2% BSA in 
TBS, pH 7.5 
IHC/ICC 
Blocking buffer II  2% normal goat (or horse) serum, 
0.25% Triton X-100 and 2% BSA in 




Add 2.94 g Tri-sodium citrate to 
1000 ml distilled H2O to make a 
volume of 1 L. The pH of the final 
solution will be 8.5. This buffer can 
be stored for up to 3 month at 4°C 
Antigen retrieval 





30 ml ethylenglycol and 25 ml 
glycerin, 45 ml 1x PBS 
Long-term storage of 
brain sections at -20°C 
DAPI stock Solution 10 mg DAPI, 2 ml DMF, 






5 ml Neurocult NS-A differentiation 
supplement + 45 ml Neurocult 
NS-A basal medium + 500 µl 
penicillin/streptomycin 
Cell culture 
EGF stocking solution 
 
50 µg EGF diluted in 5 ml PBS and 
0.1% BSA and stored as aliquots at 
-20oC 
Cell culture 
FGF stocking solution 50 µg FGF-b diluted in 5 ml PBS 
and 0.1% BSA and stored as 




32 ml EBSS reconstituted in a vial 
of ovomucoid protease inhibitor 
(10 mg) with bovine serum 










5 ml Neurocult NS-A proliferation 
supplement + 45 ml Neurocult 
NS-A basal medium +10 µl EGF 
stocking solution+5 µl FGF stocking 
solution +5 µl heparin +500 µl 
penicillin/streptomycin 
Cell culture 
PPD solution Consisted of papain (2.5 U/ml) 
Neutral protease (1 U/ml Dispase), 




2.2 Methods used for the in vivo study 
2.2.1 Immunohistochemistry as well as double- and triple-immunofluorescence 
stainings 
Cutting of serial brain tissue sections. Fixed brains were transferred to 10 and 20% 
sucrose in PBS. Subsequently, brains were frozen in precooled isopentane and stored 
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at -80°C. Serial coronal sections of one hemisphere were cut at 50 μm on a freezing 
microtome (Microm, Germany) and placed in 24-well plates each well filled with 1x 
TBS. These free-floating sections were collected in a one-in-sixth series. For 
long-term storage, brain sections of one series were placed into cryoprotectant 
solution (30ml ethylenglycol and 25ml glycerin, 45 ml PBS) and could be stored at –
20°C until further processing. 
 
Single immunohistochemistry.  
BrdU immunohistochemistry. In order to process brain slices for 
immunohistochemistry, brain sections were washed three times for 5 min with 1x 
TBS and subsequently incubated with 0.6% hydrogen peroxide in TBS for 30 min to 
inhibit endogenous peroxidases. After another washing step with 1x TBS, sections for 
quantitative detection of cells that incorporated BrdU were incubated in 50% 
formamid/2×SSC at 65°C for 2h. Then, sections were placed in 2 N HCl for 30 min at 
65°C in order to break the hydrogen bonds and therefore denature the DNA 
double-helix. After rinsing the sections in 0.1 M boric acid (pH 8.5) for 10 min to 
neutralize the hydrochloric acid and washing them with 1x TBS, they were incubated 
in blocking solution I for 1.5 h at room temperature (RT). Thereafter, sections were 
incubated in blocking buffer I containing the monoclonal anti-BrdU antibody 
produced in mouse for 48 h at 4 °C. Afterwards, sections were washed again three 
times for 5 min in 1x TBS and incubated for 1.5 h in biotinylated anti-mouse IgGs 
made in goat  diluted 1:600 in blocking solution II at RT for 2 h. Sections were then 
washed and processed with avidin-biotinylated horseradish peroxidase complex 
(ABC) in 1x TBS for 1 h at RT. After another washing step the binding sites of the 
antibodies were visualized using 3,3'-Diaminobenzidine (DAB Substrate Kit). The 
reaction was stopped by transferring the slices into 1x TBS. Subsequently, sections 
were mounted on slides, were left to dry at least overnight and were coverslipped 
with VitroClud. 
 
MCM2, NeuroD and DCX immunohistochemistry. MCM2 indicated proliferating 
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cells, NeuroD is expressed in mitotic active cells of the neuronal lineage and 
DCX is primarily expressed in post mitotic immature neurons. The staining 
protocol resembles the BrdU immunohistochemistry protocol above with some 
changes as described in the following. After sections had been incubated in 0.6% 
H2O2 in 1x TBS for 30 min and washed with 1x TBS, an antigen retrieval was 
performed. For the detection of NeuroD and MCM2, sections were incubated with 10 
mM sodium citrate buffer (pH 8.5) for 15 min at 90°C twice. For the detection of DCX, 
sections were incubated with 10 mM sodium citrate buffer (pH 8.5) for 35 min at 
80°C. The primary antibodies used were polyclonal anti-MCM2 antibodies made in 
goat (1:1000), polyclonal anti-NeuroD antibodies produced in goat (1:600), and 
polyclonal anti-DCX antibodies made in goat (1:500). For all blocking solutions 
inclusive the antibody solution normal horse serum was used instead of normal goat 
serum. Subsequently, sections were incubated with biotinylated anti-goat IgGs made 
in horse (for NeuroD 1:500, MCM2 1:1000 and DCX 1:1000) (Vector Laboratories, 
Burlingame, CA, USA).  
 
Double- and triple-immunofluorescence staining.  
In order to study the final cell type, we performed a double and 
triple-immunoflurorescent labeling of BrdU with neuronal nucleus (NeuN) as a 
marker for mature neurons, with GFAP as a marker for astrocytes, with adenomatous 
polyposis coli (APC) as a marker for oligodendrocytes and with ionized calcium 
binding adaptor molecule 1 (Iba-1) as a marker for microglia. Brain sections were 
incubated in 50% formamid/2×SSC at 65°C for 2 h and then placed in a 2 N HCl 
solution for 30 min at 65°C. After rinsing of sections in 0.1 M boric acid (pH 8.5) for 
10 min and washing with 1x TBS, sections were incubated then in blocking solution I 
for 60 min. Thereafter, sections were incubated in blocking buffer I containing a 
mixture of three different antibodies produced in different species (monoclonal rat 
anti-BrdU, monoclonal mouse anti-NeuN and polyclonal rabbit anti-GFAP) or mixture 
of two different antibodies produced in different species (monoclonal rat anti-BrdU 
and polyclonal rabbit anti-GFAP; monoclonal rat anti-BrdU and monoclonal mouse 
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anti-APC; monoclonal rat anti-BrdU and polyclonal rabbit anti-Iba-1) for 72h at 4°C. 
After removing the primary antibodies by washing the sections three times with 1x 
TBS, sections were incubated in blocking buffer II containing a mixture of three 
different secondary antibodies (Donkey anti-rat IgG conjugated with Alexa Fluor 488; 
Donkey anti-mouse IgG conjugated with Alexa Fluor 555 anti-mouse and Donkey 
anti-rabbit IgG conjugated with Alexa Fluor 350).  
 
2.2.2 Quantification of immunolabeled cells  
Cells immunolabelled for light microscopy by applying the ABC method and 
DAB as substrate of the peroxidase were counted in different layers of the DG 
[MCM2, NeuroD and DCX: in the subgranular zone (SGZ) and in the granule cell 
layer (GCL) (SGZ-GCL); BrdU: in the SGZ-GCL, molecular layer (ML), and in the 
hilus] using an unbiased stereology procedure (Stereo Investigator from MBF 
Bioscience). In more detail, immunoreactive (ir) cells were counted using the 
optical fractionator method (with a counting frame of 150 by 150 µm and a 
sampling grid of 150 by 150 µm). First section was randomly selected and 
every 6th succeeding section throughout the septal-temporal axis of the 
hippocampus was analyzed. To estimate the total number of new cells, the cell 
count for each hippocampus was multiplied by 6 since as only 1/6 of all 
sections were analyzed. We also analyzed the volume of hilus, SGZ-GCL and ML 
on the septal and temporal DG separately when counting the number of 
BrdU-positive cells with Stereo Investigator automatically. 
 
Using Stereo investigator to perform the quantitative analysis allows an 
accurate, unbiased estimation of the number, length, area, and volume of cells 
in certain tissue (Keuker et al., 2001). We estimated cell number according to 
the following equation (West et al., 1991):  
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In this equation, N is the estimate of total cell number; Q- is the number of 
units counted; the section sampling fraction (ssf) corresponds to the ratio 
between the sections we analysed and the total number of sections needed to 
section the entire tissue; And the area sampling fraction (asf) represents the 
proportion of the sectional area which is investigated within the sampled 
sections; The thickness sampling fraction (tsf) is the ratio between the height 
of the disector and the section thickness. In our study, we chose the ssf 
according to the method mentioned in Keuker’s paper (Keuker et al., 2001). In 
details, 15-20 sections at equally spaced intervals along the hippocampal 
formation should be selected and one hippocampus is on average of 115 
sections, so every 6th section was selected and about 20 sections for one study. 
Then the ssf was 1/6. The asf is the ratio of the counting frame area and the 
area between the optical disector positions in the x and y directions: 
asf=a(frame)/A(x,y step) (see Fig.9). In our case, a(frame) was equate to A(x,y 
step), so asf in our experiment is 1. The measured section thickness in our 
experiment was between 17 and 21 μm and we used an optical disector height 
of 15 μm. When we count the number of cells, we excluded the cell which 
touched the exclusion sides of the optical disector: the top, the front and the 
left side. In Fig. 9, no. 1 cell is not counted because it touches the left 
exclusion side. The cell of no. 2 is counted because it lies completely within 
the optical disector and no. 3 cell is counted because it is partly inside the 
optical dissector. 




Fig.9. Schematic representation of a section with optical disector counting locations (Keuker 
et al., 2001) 
 
For the quantification of BrdU/NeuN double stained cells, we counted 
BrdU-positive cells in the ML, SGZ, GCL and hilus which were co-labeled with 
NeuN or not. From each animal, 20 BrdU-positive cells within hilus, 20 
BrdU-positive cells within SGZ, 10 BrdU-positive cells within GCL and 20 
BrdU-positive cells within ML were randomly chosen and analyzed using a 
BX40 microscope from Olympus (Tokyo, Japan) equipped with a motorized 
stage controller and pictures were captured with the program “Cell” (Olympus). 
Then, the percentage of cells which were co-labeled with NeuN was calculated. 
All assessments were done by experimenters blind to the treatment group of 
each brain section. 
 
2.2.3 Statistical Analysis 
Data were expressed as mean ± standard error (SEM). As group size was 
limited to 6-8 rats and first analyses of results showed that obtained data were 
not normally distributed and variances of groups were not equal, we carried 
out statistical analyses using non-parametric tests (SPSS 16.0 software). 
Group-wise comparisons using the Mann-Whitney U-test were performed only 
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if a p-value of <0.1 in the Kruskal–Wallis test had indicated the presence of 
differences between the five experimental groups. P-values of <0.05 were 
considered to be statistically significant and 0.05<p<0.1 were defined as a 
trend. 
 
2.3 Methods used for the in vitro study 
2.3.1 Isolation and identification of the neural stem cells  
Both hippocampi of Wistar Rat were dissected mechanically under 
Stereomicroscope (Olympus, Japan) and transferred to a 55 mm plate (CellStar, 
Carrollton, TX, USA) containing pre-cooled (using water ice) Dulbecco's 
Phosphate-Buffered Saline (D-PBS) plus 2% glucose. After dissections of all 
hippocampi had been completed, tissue was transferred in 
Papain-Protease-DNase (PPD) solution into a 15 ml conical tube and a 1 ml 
pipettor with sterile plastic tips was used to triturate tissue pieces 
approximately 50 times until a “milk”-like solution was formed. During 
titration, the pipettor was pressed against the bottom in order to generate 
resistance for a better breaking up of the tissue, and to avoid the production 
of bubbles. Then, we incubated the milk”-like solution in a 37°C water bath 
(the optimal working temperature of the PPD solution) for 30 min in order to 
break the tissue completely. Next, the tube was left for about 5 min 
undisturbed to allow the undispersed pieces of tissue to settle. Then, the 
supernatant was transfered to a new sterile 15 ml conical tube and one ml 
Inhibitor working solution was added to stop PPD digestion. Afterwards, we 
centrifuged this supernatant at 110 g (800 rpm using a centrifuge from Bio-Rad 
Laboratories, Hercules, CA, USA) for 7 min and discarded the supernatant. 
Pellets were then resuspended with 5 ml pre-warmed proliferation culture 
medium and cell suspension were let flew through a 40 μm cell strainer 
(without pressure) (BD Falcon, Durham, NC, USA). Next, additional 2 ml culture 
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medium were added and aspirated in total volume to a T25 flask (Corning, 
Tewksburg, MA, USA). Incubation was done in a 37°C incubator.  
 
Cells were passaged every 7 days as described in the following:. We pipetted 
media into a 15 ml conical tube and washed back down the flask to harvest as 
many spheres as possible with 1 ml fresh pre-warmed proliferation culture 
medium. Solution was centrifuged at 110 g for 7 min and supernatant was 
discarded. Pellet was re-suspended with 1ml pre-warmed PPD solution and 
incubated for 10 min at 37°C Water Bath. After adding 1 ml inhibitor working 
solution, solution was centrifuged at 110 g for 7 min at RT and supernatant 
was discarded again. Then, pellet was re-suspended with 5 ml fresh 
pre-warmed proliferation culture medium to get a single cell suspension. We 
transferred all of the solution into a T25 flask (Corning, NY, USA), added 
additional 2 ml fresh culture medium and cells were incubated at 37°C and 5% 
CO2. 
 
To identify cultured cells, we stained neurospheres for nestin (a marker for 
neural stem cells) and studied whether cultured cells have pluripotent ability 
to differentiate into different types of cells (the method of differentiation see 
2.3.5 Differentiation assay). After the neurospheres had been formed after 
approximately 2 days of incubation in proliferation medium, they were plated 
on poly-L-ornithine/laminin-coated coverslips and we let them grew in 
proliferation culture medium. After neurospheres had been attached on the 
coverslips (about 2h), they were fixed with 4% PFA and immunostained for 
nestin.  
 
The method of coating coverslips is described as follows: we diluted 
poly-L-ornithine with D-PBS from the stock concentration (10 mg/ml) to yield 
50 μg/ml working solution. 250 μl working solution was added per well in 24 
well plate containing 12 mm round cover glass (Neuvitro,  El Monte, CA, USA) 
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and incubated overnight. Then, coverslips were rinsed twice with D-PBS and 
incubated with laminnin (Sigma, St Louis, MO, USA) solution for at least 30 min. 
Laminin used for that had been pre-diluted to a final concentration of 5 μg/ml 
with D-PBS. After rinsing twice with D-PBS, we let them dry. 
 
2.3.2 Treatment of NSCs with STZ 
STZ was diluted in 0.1 M citrate buffer (pH 4.5) to a 0.5 M stocking solution. 
After cells had been passaged 2 times, they were incubated with STZ at 
concentrations of 0, 1, 2.5, 5 and 10 mM. With four days incubation in STZ 
containing medium the number of neurospheres was counted with the help of 
a BX40 microscope from Olympus (Tokyo, Japan). For further experiments, we 
selected a suitable concentration of STZ to study its effects on proliferation, 
differentiation as well as insulin/IGF signaling pathway changes. 
 
2.3.3 Proliferation assay 
In order to study the effect of STZ on the proliferation of NSCs, the number 
and size of neurospheres (size > 5 cells) and the absolute number of NSCs have 
been evaluated. After passaging the cells for 2 times, NSCs were seeded into 
Cellstart™ substrate-coated 96-well plates (Life Technologies, Gaithersburg, 
MD) with the density of 2,000 cells per well. For estimating the number of 
neurospheres per well, they were counted using the BX40 microscope at 10× 
magnification. Then, for evaluating the mean size of neurospheres, they were 
imaged (about 40 images per group) by the microscope equipped with a 
motorized stage controller and pictures were captured with the program “Cell” 
(Olympus) and then analyzed with Image-Pro-Plus 5.0 software (Media 
Cybernetics, Rockville, MD, USA).  
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Proliferation of the NSCs was also studied by using a BrdU incorporation assay. 
We dissected the neurospheres with PPD solution into single cell suspension 
and seeded these cells on poly-L-ornithine/laminin-coated coverslips at the 
density of 10,000 cells per well with or without 2.5 mM STZ. After two days 
incubation, 10 μM BrdU was applied to the cultured cells for 4 h to label 
proliferating cells. Before incubation was started, BrdU stocking solution (10 
mM) had been diluted with D-PBS. Then, cells sticking on coverslips were fixed 
with 4% PFA and immunostained with mouse anti-BrdU antibody as decribed 
in the following: Coverslips were washed three times with TBS for 5 min and then 
were placed in 1 N HCl for 10 min at 37°C in order to break the hydrogen bonds and 
therefore denature the DNA double-helix. After rinsing the coverslips in 0.1 M boric 
acid (pH 8.5) for 10 min to neutralize the hydrochloric acid and washing the 
coverslips with 1x TBS for three times, they were incubated in blocking solution I for 
1.5 h at RT. Thereafter, coverslips were incubated in blocking buffer I containing the 
monoclonal anti-BrdU antibody produced in mouse for 48 h at 4°C. Afterwards, 
coverslips were washed again three times for 5 min in 1x TBS and incubated for 1.5 h 
in Alexa 555 anti-mouse IgGs made in donkey diluted 1:600 in blocking solution II at 
RT for 2 h. After washing coverslips with 1x TBS three times, they were incubated 
with 300 nM DAPI for 5 min at RT, and then washed again. Finally, coverslips were 
mounted to slides with Fluoro mount.  
 
2.3.4 Migration assay 
We collected rat neurospheres and centrifuged at 110 g for 7 min. After 
removing all of the supernatant, the pellet was re-suspended with 5 ml 
differentiation culture medium. About 10-15 neurospheres/well were plated 
on poly-L-ornithine/laminin-coated coverslips in a 24-well plate (Sarstedt, 
Nümbrecht, Germany) and were incubated in differentiation culture medium. 
After neurospheres were attached on the coverslips (about 2 h), medium was 
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aspirated and changed to differentiation cell culture medium with or without 
2.5 mM STZ. Two days later, pictures were taken using the BX40 microscope 
and then analyzed with Image-Pro-Plus 5.0 software. 
 
In order to quantify the migration of newborn cells, we traced the outermost 
area, where to newborn cells had migrated to (starting from the neurosphere, 
which was located in the middle as shown in Fig.10A). Using the 
Image-Pro-Plus 5.0 software the average diameter (D1) of this area defined as 
S1 was estimated (Fig.10B). Then, we traced the area of the respective 
neurosphere (S2), the average diameter D2 could be calculated automatically 
by our program (Fig.10B). The average migration distance (R) for one 
neurosphere can be calculated according to following formula:  
𝑅 = (𝐷1 − 𝐷2)/2 
  
 
Fig.10. Method of estimation of newborn cell migration 
The picture of neurosphere together with the cells migrated from the neurosphere was taken up 
by microscope (A). The area of neurosphere and migrating cells were traced by Image-Pro-Plus 
5.0 software (A) and generated to trace image (B).  The average diameter of neurosphere 
and migrating cells can be calculated automatically by program. The average migration 
distance (R) for one neurosphere was estimated according to following formula:  𝑅 =
(𝐷1 − 𝐷2)/2. S1: the area of migrating cells. S2: the area of the neurosphere. D1: the 
average diameter of the area of migrating cells. D2: the average diameter of the area of 
the neurosphere. 
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2.3.5 Differentiation assay  
To characterize the phenotype of differentiating NSCs and the effect of STZ on 
this differentiation process, NSCs were collected and then promoted to 
differentiate into different types of cells. In detail, after passaging for two 
times in proliferation culture medium, we collected rat neurospheres and 
centrifuged at 110 g for 7 min and discarded the supernatant. The pellet was 
re-suspended with 5 ml differentiation culture medium. Neurospheres were 
then transferred onto pre-coated cover glasses in a 24-well plate with the 
density of 10-15 neurospheres per well. After neurospheres were attached on 
the coverslips (about 2 h), the culture medium was exchanged to 
differentiation cell culture medium with or without 2.5 mM STZ. After cells 
were incubated in differentiation culture medium for 2 days, medium was 
removed from each well and .5 ml of the fixative 4% PFA was added. After an 
incubation for 30 min at RT in the fixative cells were immunostained using 
Tuj-1 and GFAP antibodies. 
 
2.3.6 Detection of insulin receptor and glucose transporter 3 protein 
We immunofluorescently stained the IR and GLUT3 proteins in both, NSCs and 
differentiated cells. For analyzing differentiated cells, the methods used are 
the same as in protocol above (2.3.5 Differentiation assay) and immunostained 
for IR as well as GLUT3. For the staining of NSCs, we generated a single cell 
suspension out of neurospheres with the help of PPD solution and seeded 
these cells on poly-L-ornithine/laminin-coated coverslips at the density of 
10,000 cells per well with or without 2.5 mM STZ. Two days later, we fixed 
these cells with 4 % PFA and performed immunfluorscence stainings. 
 
For immunofluorescence staining with antibodies against IR and GLUT3 proteins, 
protocols were similar to the BrdU staining protocol (see 2.3.3), but without 1 N HCl 
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for 10 min and boric acid incubation steps. For differentiation studies, coverslips 
were incubated in blocking buffer I containing the monoclonal anti-Tuj-1 antibody 
(produced in mouse) and polyclonal rabbit anti-GFAP for 48 h at 4°C after rinsing 
coverslips in 1x TBS three times for 5 min. Then coverslips were washed again three 
times for 5 min in 1x TBS and incubated for 1.5 h with Alexa 488 anti-mouse IgGs 
made in donkey and Alexa 555 anti-rabbit IgGs made in donkey diluted 1:500 in 
blocking solution II at RT for 2 h. For the detection of Nestin, IR and GLUT3 protein 
expression in NSCs and differentiating cells (Nestin only used for immunostaining of 
NSCs), coverslips were incubated in blocking buffer I containing the monoclonal 
anti-Nestin produced in mouse, anti-IR antibody produced in mouse or polyclonal 
anti-GLUT3 antibody produced in rabbit for 48 h at 4°C. Then coverslips were washed 
again three times for 5 min in 1x TBS and incubated for 1.5 h with Alexa  555 
anti-mouse IgGs made in donkey or Alexa 555 anti-rabbit IgGs made in donkey 
diluted 1:500 in blocking solution II at RT for 2 h. 
 
2.3.7 Quantitative real time PCR 
Rat neurospheres were incubated in 6-well plates (Corning, New York, USA) 
with or without STZ for 2 days. After collecting the neurospheres, total RNA 
was extracted using RNeasy kit from Qiagen following manufacturer ’s 
instructions.  
 
cDNA was synthesized with a first strand cDNA synthesis kit from Bio-Rad. 
For each reaction: 
5 × iScript reaction mix       4 μl  
iScript reverse transcriptase   1 μl 
Nuclease-free water         variable 
RNA template (200 ng)       variable 
Total volume     20 µl 




cDNA synthesis was performed in a PCR machine (e.g. Biometra, Göttingen, 
Germany) using following program: 25 °C, 5 min; 42 °C, 30 min; 85°C, 5 min and 
then 4 °C until further processing. Finally, cDNA was diluted 1:5with TE buffer. 
 
The PCR was performed in 384-well plates (life technologies, Gaithersburg, USA). For 
each reaction: 
SYBR Select Master Mix for CFX (2 ×)        5 μl 
Forward and Reverse Primers (5uM)      1 μl 
cDNA                              1 μl 
RNA template (200 ng)                 3 μl 
Total volume         10 µl 
 
The PCR reaction was carried out using a CFX384 Real-Time system from 
Bio-Rad using the following conditions: 95 °C, 2 min; 45 cycles of 95 °C, 5 sec;  
60 °C, 30 sec; 95 °C, 10 min; lastly 65°C, 5 sec.  
 
CT values were calculated using the 2
ΔΔCT method (ΔΔCT = ΔCTsample –  
ΔCTcontrol) for relative quantification. ΔCT was calculated by normalized CT 
values of samples minus CT values of GAPDH (as a reference gene). CT values 
were analyzed with the help of LinRegPCR software.   
 
2.3.8 Statistical analysis 
Data were expressed as mean ± standard deviation (SD). For STZ concentration 
determination and migration study, the data were analyzed one way analysis of 
variance (ANOVA) followed by Bonferroni post hoc test using SPSS 16.0. For the 
others, we performed a Student's t-test. P-values of <0.05 were considered to be 
statistically significant. Statistical significance is indicated as *, p <0.05; **, p <0.01. 




3.1 In vivo study results 
3.1.1 The effect of STZ icv treatment on proliferating stem/progenitor cells in 
the SGZ 
To determine the effect of STZ icv treatment on proliferating progenitor cells in 
the SGZ of the DG, hippocampal sections were stained with an antibody 
against MCM2, which is a G1-S phase-specific marker of cellular replication 
and can be used as an endogenous marker for proliferating cells (Kneissl et al., 2003). 
MCM2-immunosignals were detected in cell nuclei and often appeared in 
cluster (Fig.11A). MCM2-positive cells in the SGZ were stereologically quantified 
using the Stereo Investigator software (MBF Bioscience). Our results did not 
reveal any significant difference of the number of MCM2-positive cells between all 
treatment groups neither in septal, temporal nor in total hippocampus (Fig.11B-D). 
Even if significant group differences were missing, Fig. 11C depicts that the number 
of MCM2-positive cells seems to be increased in the temporal hippocampus of rats 1 
month after STZ icv treatment compared to the vehicle 1 month group. Moreover, 3 
months after STZ icv treatment the number of MCM2-ir cells was shown to be 
reduced by 37.1% in the septal (Fig.11B) and by 24.1% in the total hippocampus 
(Fig.11D).  




Fig.11. Effect of STZ icv treatment on the number of proliferating cells in the subgranular 
zone 
A: Representative photomicrographs display MCM2-ir cells (indicated by arrows) in the 
dentate gyrus. Notice the subcellular distribution of the MCM2 in different cell nuclei. 
We quantified MCM2-positive cells which are localized in the subgranular zone (SGZ, 
indicated by arrowheads) of the septal (B), temporal (C) and total (D) hippocampus. 
Statistical analysis did not reveal any significant difference between groups (n=6 -8 rats 
per group). Data are presented as the arithmetic mean of MCM2-positive cells per 
hemisphere ± standard error of mean (SEM). Hilus, Hi; Molecular layer, ML; granule cell 
layer, GCL. Scale bar in A represents 50 µm. 
 
                                                                                      Results 
56 
 
3.1.2 The number of immature neurons is decreased in 3 months, but not 1 
month after STZ icv treatment   
To determine possible effects of STZ icv treatment on the differentiation of 
newborn cells to neurons, we analyzed intermediate stages of AN using two 
different marker for immature neurons, NeuroD and DCX. As shown in Fig.12A and 
13A, NeuroD as well as DCX-positive cells were primarily located in the SGZ of the DG. 
The NeuroD-protein was exclusively detected in cell nuclei, whereas 
DCX-immunoreactivity was found in the cytoplasm of the cell body (without 
immunostaining of the nucleus) and the dendrites extending through the GCL 
into the ML. NeuroD is a marker for mitotic active cells of the neuronal lineage 
and DCX marks primarily post mitotic immature neurons. Quantitative 
immunohistochemistry using both AN markers resulted in significant group 
differences in the SGZ of septal (but not temporal) hippocampus with p= 0.04 
for NeuroD (Fig.12B) and p=0.01 for DCX (Fig.13B). In the total hippocampus, 
statistical analysis of DCX data revealed a trend for group differences (p=0.062; 
Fig.13D). As shown in Fig.12B, Fig.13C,D post hoc groupwise comparisons 
revealed that in the SGZ of the septal hippocampus STZ icv 3 months rats have 
significantly less NeuroD-ir cells (a decrease of 66.7%; p=0.017; Fig.12B) and 
highly significant less DCX-positive cells (a decrease of 72.5%; p=0.002; Fig.13C) 
than in vehicle icv 3 months rats. Besides these significant differences, a trend 
towards lower numbers of immunopositive cells in the STZ icv 3 months group 
compared to the STZ icv 1 month group could be shown for NeuroD in the 
septal hippocampus (p=0.073; Fig.12B) and for DCX in total hippocampus 
(0.053; Fig.13D). Comparing the data from the STZ icv 1 month rats with their 
appropriate vehicle control group and all other experimental groups, no 
significant differences could be revealed, neither analyzing NeuroD nor DCX. 




Fig.12. The number of NeuroD positive cells is reduced in the septal, but not in the 
temporal and total hippocampus, 3 months after STZ icv treatment  
A. Representative microphotographs display NeuroD-ir cells (indicated by arrows) 
primarily located in the subgranular zone (SGZ, indicated by arrowheads) of the DG. 
Notice that the NeuroD-protein is exclusively detected in cell nuclei. We quantified 
NeuroD- (B,C,D) an the SGZ of the septal (B), temporal (C) and total (D) hippocampus 
using the StereoInvestigator software. Group differences were mainly revealed in the 
septal hippocampus for NeuroD (p=0.04). B: Groupwise comparisons showed that the 
number of NeuroD-ir cells in the septal hippocampus is significantly decreased by 66.7% (p=0.017) 
in rats sacrificed 3 months after STZ icv injections (STZ 3 months) compared to rats 3 months 
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after the vehicle icv treatment (Vehicle 3 months). A trend or tendency towards less NeuroD-ir 
cells in the STZ 3 months group compared to the STZ 1 month group could also be found. Data 
are presented as the arithmetic mean of NeuroD-positive cells per hemisphere ± standard 
error of mean (SEM). #: p-value of Mann-Whitney U- test <0.1 and >0.05; *: p-value 
<0.05; **: p-value <0.01. Hi, Hilus; Scale bar in A represents 200 µm. 
 
 
Fig.13. The number of DCX positive cells is reduced in the septal, but not in the 
temporal and total hippocampus, 3 months after STZ icv treatment  
A: Representative microphotographs display DCX-ir cells (indicated by arrows) primarily 
located in the subgranular zone (SGZ, indicated by arrowheads) of the DG. Notice that 
the DCX-immunoreactivity is found in the cytoplasm of the cell body (without 
immunostaining of the nucleus) and the dendrites extending through the granule cell 
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layer (GCL) into the ML. We quantified DCX-positive cells in the SGZ of the septal (B), 
temporal (C) and total (D) hippocampus using the StereoInvestigator software. Group 
differences were mainly revealed in the septal hippocampus for DCX (p=0.01), and for 
DCX (p=0.062) also in the total hippocampus (n=6-8 rats per group). B: Groupwise 
comparisons revealed that highly significant less DCX-ir cells (up to 72.5% less; p=0.002) were 
detected in the STZ 3 months compared to the Vehicle 3 months group. C: Groupwise 
comparisons of the number of DCX-ir cells in the total hippocampus revealed 
significantly less DCX-ir-cells (p=0.021) in the STZ 3 month group in comparison to the 
Vehicle 3 months group. A trend or tendency towards less DCX-ir cells in the STZ 3 months 
group compared to the STZ 1 month group could also be detected (p=0.053). Even if significant 
group differences were missing, the number of DCX-positive cells seems to be increased in the 
hippocampus of rats of the STZ 1 month group compared to the Vehicle 1 month group (most 
pronounced in the temporal hippocampus). Data are presented as the arithmetic mean of 
DCX-positive cells per hemisphere ± standard error of mean (SEM). #: p-value of 
Mann-Whitney U- test <0.1 and >0.05; *: p-value <0.05; **: p-value <0.01. Hi, Hilus; 
Scale bar in A represents 200 µm. 
 
3.1.3 STZ icv treatment differently impacts the survival of newborn cells in 
various dentate gyrus regions  
Furthermore, we analyzed the effect of STZ icv treatment on the survival of 
newborn cells. For that, experimental rats received BrdU ip injections on 7 
consecutive days (once daily) and were sacrificed 27 days after the first 
injection. As shown in Fig.14A and B immunohistochemistry using BrdU 
antibodies resulted in several immunopositive cell nuclei in the SGZ and GCL, 
the two main regions where AN happens, but also in the hilus and ML of the 
DG. As we detected many BrdU-ir cells in these latter regions, we quantified 
the number of BrdU-positive cells not only in the SGZ including the GCL 
(=SGZ/GCL), but also in the hilus and ML (Fig.14). Interestingly, we detected 
more BrdU-ir cells in the hilus and ML than in the SGZ/GCL irrespectively of the 
treatment group. In the SGZ/GCL (Fig.14 D,G,J) stereological quantification of 
BrdU-positive cell nuclei and applying the Kruskal-Wallis test resulted in 
significant group differences in the septal hippocampus with p=0.049 (Fig.1 4D), 
but not in temporal (Fig.14G) and total hippocampus (Fig.14J). Subsequent 
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post hoc groupwise comparisons revealed that in the septal hippocampus STZ 
3 months rats have significantly less BrdU-immunoreactive (ir) cells (a 
decrease of 36.3%; p=0.048) than Vehicle 3 months rats (Fig.14D). Significant 
differences between the STZ 1 month rats and the Vehicle 1 month control 
group or the absolute control group (without any icv treatment) in the septal 
hippocampus were missing. In hilus (Fig.14C,F,I), a trend for a group difference 
applying the Kruskal-Wallis test was only found in the temporal hippocampus 
with p=0.051. As shown in Fig. 8F subsequent post hoc-analysis revealed a 
trend for more BrdU-positive cells in rats of the STZ 1 month icv group 
compared to the Vehicle 1 month icv group (p=0.052) and compared to the STZ 
3 months icv group (p=0.073). In the ML (Fig.14E,H,K), significant group 
differences were found in the temporal (p=0.039; Fig.14H) and total 
hippocampus (p=0.049; Fig.14H). In the temporal hippocampus (Fig.14H), 
pairwise comparisons revealed a trend towards higher number of 
BrdU-positive cells in the STZ 1 month icv group compared to the Vehicle 1 
month group (p=0.052) and compared to the STZ 3 months group (p=0.051). 
Moreover, a trend towards lower number of BrdU-positive cells in the Vehicle 
1 month group compared to the absolute control group with p=0.093 was 
found (Fig.14H). In the total hippocampus (Fig.14K), pairwise comparisons 
revealed a trend towards higher number of BrdU-positive cells in the STZ 1 
month group compared to the Vehicle 1 month group (p=0.082) and a trend 
towards lower number of BrdU-positive cells in the Vehicle 1 month group 
compared to the absolute control group with p=0.093. Notice, that in the hilus 
and ML much more BrdU-ir cells were detected than in the SGZ/GCL. 




Fig.14. The effect of STZ icv treatment on the number of survived BrdU-positive cells in 
the dentate gyrus 
A,B: Representative photomicrographs with different magnification of coronal sections 
through the DG immunostained with BrdU antibody. As experimental rats received daily 
BrdU ip injections on 7 consecutive days and were sacrificed 27 days after the first BrdU 
application, immunohistochemistry detection followed by quantification of BrdU-ir cells 
was performed to assess the effect of STZ icv treatment on surviving newborn cells. 
Notice that the BrdU is exclusively detected in cell nuclei  (as indicated by arrows in B). 
BrdU-positive cells were found and quantified in the hilus (Hi; C,F,I), in the subgranular 
zone (SGZ, indicated by arrowheads) including the granule cell layer (SGZ/GCL; D,G,J) and 
in the molecular layer (ML; E,H,K) of the DG (n=6-8 rats per group). Moreover, we 
quantified BrdU-positive cells in the septal (C,D,E), the ventral (F,G,H), and the total 
hippocampus separately. Notice that we counted more BrdU-positive cells in the hilus 
and in the ML than in the SGZ/GCL layer, where stem cells are and neurogenesis primarily 
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takes place in the adult hippocampus. C,F,I: In Hilus, a trend towards more BrdU-positive 
cells in the STZ 1 month group compared to the Vehicle 1 month group as well as 
compared to the STZ 3 months group could be shown exclusively in the temporal 
hippocampus. D,G,J: Excusively in the SGZ/GCL of the septal hippocampus, the STZ 3 
month group possessed significantly less BrdU-positive cells than the Vehicle 3 months 
group (p=0.048). E,H,K: In the ML, only small differences could be revealed. In the 
temporal hippocampus a trend towards more BrdU-ir cells was detected in the STZ 1 
month group compared to the Vehicle 1 month and compared to the STZ 3 months group. 
Additionally, a trend towards lower BrdU numbers in the Vehicle 1 month group 
compared to the absolute control group was shown. Data are presented as the arithmetic 
mean of BrdU-positive cells per hemisphere ± standard error of mean (SEM). #: p-value 
of Mann-Whitney U- test <0.1 and >0.05; *: p-value <0.05. Scale bar in A represents 200 
µm and in B represents 50 µm. 
 
3.1.4 STZ icv treatment did not alter the rate of neuronal differentiation in 
the subgranular zone and granule cell layer  
Triple stainings using antibodies detecting BrdU, NeuN (a marker for mature 
neurons), and GFAP (a marker for astrocytes) were performed to analyze the 
final phenotype of newborn BrdU-ir cells which survived up to 27 days. As 
shown in Fig.15A-C, single stained BrdU-positive cells (Fig.15A,C) but also 
double stained BrdU/NeuN-positive cells (Fig.15B) could be found. In a 
quantitative approach we focused on the neuronal phenotype and exclusively 
analyzed the percentage of BrdU-positive cells that expressed NeuN 
(Fig.15D-K). Statistical analyses applying the Kruskal-Wallis test did not reval 
any significant differences between experimental groups neither in Hilus, SGZ, 
GCL, and ML nor in septal or temporal hippocampus. Notice that 
BrdU-ir/NeuN-ir cells were almost exclusively found in the SGZ (Fig.15E,I) and 
GCL (Fig.15F,J), the neurogenic regions of the DG, and not in the hilus 
(Fig.15D,H) and ML (Fig.15G,K).  
 




Fig.15. The percentage of newborn neurons in the dentate gyrus is not affected by STZ icv 
treatment  
A-C: Phenotype analysis of BrdU-ir cell nuclei in the DG. Representative 
photomicrographs display BrdU/NeuN/GFAP triplestaining (A) and BrdU/NeuN double 
stainings (B, C). A: Merged image of BrdU (green), NeuN (red) and GFAP (blue) did not 
show any co-localization. B,C: Merged images display one cell in the subgranular zone 
(SGZ, indicated by arrowheads) double labeled for BrdU and NeuN (yellow cell nucleus in 
B, indicated by an arrow) and several BrdU-positive cells in the SGZ and the hilus without 
double labeling (green nuclei in C, indicated by arrows). D-K: Quantitative estimation of 
the percentage of BrdU-positive cells that express NeuN detected in hilus (D,H), SGZ (E,I), 
granule cell layer (GCL; F,J) and molecular layer (ML; G,K) didn`t resulted in any differences 
between experimental groups (n=6-8 rats per group), neither in the septal hippocampus 
(D-G) nor in the temporal hippocampus (H-K). Notice that the highest number of 
BrdU/NeuN double stained cells was detected in the SGZ and GCL, where ad ult 
neurogenesis happens. Data are presented as mean percentage of BrdU/NeuN double 
stained cells ± standard error of mean (SEM). Scale bar in C represents 50 µm for A -C. 
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3.1.5 Phenotype analysis of BrdU-positive cells in the hilus and molecular layer 
revealed newborn oligodendrocytes but not newborn microglia  
As the quite numerous BrdU-positive cells localized in the hilus and ML, which 
had survived up to 27 days, were found to have no neuronal phenotype (see 
Fig.15D,H and G,K), double staining using antibodies detecting BrdU and APC 
(a marker for oligodendrocytes) and detecting BrdU and Iba-1 (a marker for 
microglia) were performed in addition to the already shown triple staining of 
BrdU/NeuN/GFAP (see Fig.15A) to further analyze their possible cellular 
phenotype. As shown in Fig.16, some BrdU-ir cells in ML displayed also APC 
immunoreactivity (Fig.16F), but we could not detect BrdU/GFAP-double 
stained cells (Fig.16C) and BrdU/Iba1 double stained cells (Fig.16I) in the ML. 
Thus, with exception of some newborn oligodendrocytes we could not identify 
the cell type of most of the BrdU-positive cells found in the ML. 
 
Fig.16. Some newborn cells in the molecular layer are oligodendrocytes  
Phenotype analysis of BrdU-positive cells in the ML and in the hilus. Phenotype analysis 
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was performed for approximately 27 days survived cells using double labeling 
immunofluorescence staining. (A-C) Representative images display a section labeled for GFAP, 
a marker for astrocytes (A, red, indicated by red arrows) and BrdU (B, green, indicated by a green 
arrow). In B unspecific stained small vessels were visible. The merged image (C) shows that these 
newborn cells are located in close vicinity of both, GFAP-positive processes and small vessels (see 
unspecific labeling of small vessels in yellow), but BrdU+/GFAP+ cells were not observed. (D-F) 
Representative images show a section labeled for APC, a marker protein of oligodendrocytes (D, 
red, indicated by red arrows) and BrdU (E, green, indicated by a green arrow). The merged image 
(F) shows one cell double labeled for BrdU and APC (indicated by a yellow arrow) in addition to 
single stained APC-ir cells (indicated by red arrow). (G-I) Representative images show a section 
labeled for Iba-1, a microglia marker protein (G, red, indicated by red arrows) and BrdU (H, 
green, indicated by a green arrow). The merged image (F) does not show any double labeling 
(red arrows indicate single-stained Iba-1 positive microglial cells and the green arrow indicates 
the single-stained BrdU-ir cell nucleus). 
 
3.1.6 The volume of different dentate gyrus subregions is not affected by the STZ 
icv treatment 
In addition to the counting of BrdU-positive cells in all subregions of the DG 
(hilus, SGZ/GCL and ML), we estimated the volume of these subregions using 
stereological methods as outlined in Materials and Methods. Statistical analysis, 
however, did not reveal volume differences as depicted in Fig.17. Thus, STZ icv 
treatment did not produce overall changes in the volume of these different DG 
subregions, neither in the septal nor in the temporal hippocampus. 




Fig.17. The volume of different dentate gyrus subregions is not affected by the STZ icv 
treatment 
The volume of the hilus (A,D,G), subgranular zone including the granule cell layer 
(SGZ/GCL; B,E,H) and the molecular layer (ML; C,F,I) in the DG of each brain was assessed 
with the help of the StereoInvestigator software. Statistical evaluation of these measurements 
did not reveal any differences between experimental groups (n=6-8 rats per group), neither in 
the septal (A-C), the temporal (D-F), nor in the total hippocampus (G-I). Data are presented as 
the mean volume in mm3 per hemisphere ± standard error of mean (SEM) . 
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3.2 In vitro study results 
3.2.1 Identification of neural stem cells and their progeny 
In the presence of the “complete” proliferation cell culture medium, the 
hippocampus-derived NCSs proliferated quickly forming small free-floating clusters of 
NSCs first, and then forming larger so-called neurospheres after several days 
(Fig.18A). Neurosphere cells could be stained by an anti-nestin antibody (Fig.18B). 
Nestin is a marker for neural progenitor cells, which give rise to neurons as well as 
glial cells (Wiese et al., 2004). After replacing the proliferation cell culture medium to 
the differentiation cell culture medium, cultivation of neurospheres continued for 2 
days. During this period of time differentiation and migration of these cells had been 
initiated and then verified via immunofluorescence staining using antibodies 




Fig.18. Identification of the cultured neural stem cells  and their progeny 
(A): Cells originating from adult rat hippocampus proliferated and formed free-floating 
neurospheres already one week after cultivating had started. (B): A representative 
neurosphere after the second passage shown to be immunoreactive for nestin, a marker for 
neural stem cells (red) and counterstained with 4',6-diamidino-2-phenylindole (DAPI) (blue). (C): 
A neurosphere after the second passage followed by cultivating in differentiation culture medium 
for 2 additional days. Some cells originating from the neurosphere display immunoreactivity of 
Tuj-1, a marker for immature neurons (green) and most of them display immunoreactivity for 
GFAP, a marker for astrocytes (red). DAPI was used for counterstaining (blue) (C). Scale bar in A, B 
and C represents 50 µm. 
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3.2.2 STZ reduces the proliferation of neural stem cells 
To determine the STZ concentration with optimal effectiveness on the proliferation of 
neural stem cells in vitro, separated neural stem cells (after the second passage) were 
seeded in a 96 well plate and treated with different concentrations of STZ (0, 1, 2.5, 5 
and 10 mM). After four days, dose-dependent effects of STZ on the number of 
neurospheres were analyzed (Fig.19). Compared to the control group (0 mM STZ) 
treatment with different STZ concentrations decreased the number of neurospheres 
in a dose-dependent manner (1mM: 29.3%; 2.5 mM: 53.3%; 5 mM: 67.3% and 10 
mM: 79.0%) (Fig.19). Considering middle-sized effects of STZ trying to avoid toxic 
effects of STZ, we chose a concentration of 2.5 mM STZ for all subsequent 
experiments. 
 
Fig.19. The number of neurospheres was decreased at various doses of STZ  
Single cells separated from neurospheres after the second passage were incubated with 
various concentrations of STZ (0, 1, 2.5, 5 and 10 mM). After four days, STZ exhibits a 
dose-dependent effect on the form of neurospheres. Data are presented as the number 
of neurospheres per well ± standard deviation (SD). *: p-value <0.05; **: p-value <0.01. 
 
One experiment dealt with the time-dependency of the effectiveness of STZ on the 
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proliferation of these neural stem cells (=on the generation of new neurospheres). As 
shown in Fig.20, from experimental day 2 on highly significant less neurospheres 
were counted in the STZ-containing culture medium compared to neurospheres in 
medium without STZ, whereupon the difference in number between these two 
treatment groups increased with the number of days of incubation (2 days by 25.1%; 
4 days by 53.85%; 6 days by 59.8%; 8 days by 62.8%). 
 
Fig.20. The number of neurospheres was decreased at various days of STZ  
Single Cells separated from neurosphere after the second passage were incubated with 2.5 
mM of STZ for different days. STZ exhibits a time-dependent effect on the form of 
neurospheres. Data are presented as the number of neurosphere per well ±standard 
deviation (SD). *: p-value <0.05; **: p-value <0.01. 
 
As the size of each neurosphere reflects the proliferative capacity of neural 
stem cells each neurosphere is composed of, we measured the diameter of 
neurospheres after 2 days of incubation with or without STZ. A dramatically 
reduced mean size (by 32.5%) of neurospheres incubated in medium containing STZ 
compared to neurospheres incubated in medium without STZ was observed (Fig.21). 




Fig.21. The diameter of neurospheres was decreased in consequence of STZ treatment  
Single cells separated from neurospheres after their second passage were incubated in 
medium with 2.5 mM STZ for 2 days. Then, resulting neurospheres were pictured and the 
size of each neurosphere was analyzed with Image-Pro-Plus 5.0 software. Data are 
presented as the mean diameter of neurospheres ± standard deviation (SD). *: p-value 
<0.05; **: p-value <0.01. 
 
BrdU is widely used to monitor cell proliferation as given in excess it incorporates 
into the DNA of dividing cells during their S-phase (Taupin, 2007). Under control 
conditions (without STZ treatment) about 20% of neural stem cells incorporated 
BrdU in 4 h as verified by immunofluorescence staining using an antibody detecting 
BrdU and DAPI counterstaining (Fig.22). When treated with STZ for 2 days, the 
fraction of BrdU-positive cells was decreased significantly (p=0.000661) and only 
about 12.9% of all cultured stem cells incorporated BrdU in 4 h (Fig.22C). 




Fig.22. STZ treatment decreases the number of Bromodeoxyuridine (BrdU)-positive 
neural stem cells  
Cells from neurospheres after their second passage were incubated in medium with (B) 
or without (A) 2.5 mM STZ for 2 days. These cells were then pulsed with BrdU (10  μM) 
for 4 h and fixedin 4% PFA for immunofluorescence stainings. Then, cells were pictured 
and analyzed with Image-Pro-Plus 5.0 software. Proliferation of neural stem cells was 
measured by BrdU-immunopositive nuclei, which were shown by red fluorescent 
immunostaining. The total cells were shown by staining with 4',6-diamidino-2-phenylindole 
(DAPI) (Blue). (C): The percentage of BrdU-positive cells from 10 replicate images was 
determined from different areas. Data are presented as the percentage of BrdU-positive 
cells of DAPI-positive cells ± standard deviation (SD). *: p-value <0.05; **: p-value <0.01. 
Scale=50 µm. 
 
3.2.3 Effect of STZ on the migration of newborn differentiating cells  
In SGZ, neural stem cells are shown to differentiate into immature neurons and 
then newly generated neurons migrate a short distance to the GCL to become 
granule neurons (Ming and Song, 2005). In order to study whether STZ treatment 
influences the migration capabilities of cells starting to differentiate, 10-15 
neurospheres were plated onto poly-L-ornithine/laminin-coated coverslips in 24 well 
plates and were incubated in differentiation culture medium with or without 
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different concentrations of STZ for 2 days. As shown in Fig.23, STZ treatment for 2 
days did not significantly affect the migration of newborn cells. 
 
Fig.23. STZ does not influence the migration of differentiating cells  
10-15 neuropheres were plated onto poly-L-ornithine/laminin-coated coverslips in 24 
well plates and were incubated in differentiation culture medium with or without STZ for 
2 days. Then microscope images were taken and analyzed with Image-Pro-Plus 5.0 
software. (A): Representative image of migrating cells originating from a neurospher e. 
Scale bar represents 100 µm. (B): Average migration distances of neural stem cells with 
(0.1 mM, 0.5 mM, 1.0 mM and 2.5 mM) or without (0 mM) STZ treatment. Data are 
presented as the distance measured from the respective cell and the rim of the 
neurosphere ± standard deviation (SD). *: p-value <0.05; **: p-value <0.01. 
 
3.2.4 STZ affects the neuronal fate of newborn cells  
The neuronal phenotype of differentiating cells was determined by using Tuj-1 as a 
marker of immature neurons and GFAP as a marker for astrocytes. After 2 days of 
incubation in the differentiation medium, Tuj-1- and GFAP-positive cells were found 
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in immediate vicinity of the neurospheres (Fig.18C). Our results demonstrate that the 
percentage of cells immunoreactive for Tuj-1 were significantly lower in the STZ 
treatment group in comparison to those in the normal control group (a decrease of 
45.5%; p=0.003) (Fig.24C). However, the percentages of cells immunopositive for 
GFAP were not significantly different between the STZ treatment and the control 
group (Fig.24D).  
 
Fig.24. STZ decreases the number of newborn cells differentiating to neurons but has 
no effect on the differentiation to astrocytes  
Cells originating from neurospheres (after the second passage) were incubated  in 
differentiation culture medium with or without 2.5 mM STZ for 2 days, then stained with 
antibodies. Microscope images were taken and analyzed with Image-Pro-Plus 5.0 
software. (A-B): Representative images of already differentiated cells as determined by 
Tuj-1 (green) and GFAP (red) immunocytochemistry after 2 days of incubation with (B) or 
without STZ (A). Nuclei of all cells were counterstained with 4',6-diamidino-2-phenylindole 
(DAPI) (blue). (C): The percentage of Tuj-1-positive cells using 10-12 replicate images was 
determined. (D): The percentage of GFAP-positive cells from 10-12 replicate images was 
determined from the periphery of the neurosphere colony area. In both cases, C and D, 
the analysed area comprises the periphery of the respective neurosphere. Data are 
presented as the percentage of Tuj-1 (C) or GFAP (D) positive cells of all DAPI positive 
cells ± standard deviation (SD). *: p-value <0.05; **: p-value <0.01. Scale bar represents 
50 µm. 
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Furthermore, after two days of differentiation in the presence of STZ, the 
number and length of Tuj-1-positive cell processes seemed to be reduced 
compared to the number and length of cell processes of the control group 
(without STZ treatment) (Fig.25B).  
 
 
Fig.25. STZ impaired the growth of processes in Tuj-1 positive cells 
Cells originating from neurospheres (after the second passage) were incubated in 
differentiation medium containing 0 or 2.5 mM STZ for 2 days, then stained with 
antibodies detecting Tuj-1. Representative image of processes in Tuj-1 positive cells 
(green) after 2 days of treatment with (B) or without STZ (A) counterstained with 
4',6-diamidino-2-phenylindole (DAPI) (Blue). Scale=20 µm. 
 
3.2.5 Effect of STZ on insulin receptor, insulin-like growth factor 1 and 
glucose transporter 1 and 3 mRNA expression in neural stem cells 
In the STZ icv treatment rat model (in vivo), brain glucose/energy metabolism 
abnormalities were found in all hippocampal subfields, such as decreased glucose 
utilization (Duelli et al., 1994). GLUT3 is most known for its specific expression in 
neurons and has originally been designated as the neuronal glucose 
transporter (Kayano et al., 1988). But, GLUT3 has been found to be expressed 
in adult NSCs, too (Maurer et al., 2006). Furthermore, in the STZ icv rat model, 
insulin system dysfunction was found and insulin receptor expression 
decreased significantly in hippocampus (Grunblatt et al., 2007). In order to 
study the effect of STZ on the expression of glucose metabolism related genes, 
                                                                                      Results 
75 
 
we collected neurospheres after incubation in proliferation medium for 2 days 
and then performed qRT-PCR for the detection of relative mRNA expression of 
IR, IGF1, GLUT1 as well as GLUT3. In Fig.26 the relative expression levels of GLUT3 
mRNA is shown to be reduced by 46.4% (p=0.041) in consequence of STZ treatment. 
Besides this significant difference, a trend towards lower relative mRNA 
expression was foung for IGF1 in the STZ treatment group compared to the 
control group (p=0.057; Fig.26). Other than these, the expression of IR, IGF1 
and GLUT1 in NSCs seems to be unaffected by STZ treatment (Fig.26). 
  
 
Fig.26. Effect of STZ on the gene expression of insulin receptor, insulin-like growth factor 1 and 
glucose transporter in neural stem cells 
Cells originating from neurospheres (after the second passage) were incubated  in 
proliferation culture medium in a 6-well plate with or without 2.5 mM STZ for 2 days, then 
cells were collected and analyzed via qRT-PCR. The relative mRNA expression of glucose 
transporter 3 (GLUT3) is reduced by 46.4% (p=0.041) in consequence of STZ treatment. 
No significant difference of the relative mRNA expression of insulin receptor (IR), 
insulin-like growth factor 1 (IGF1), glucose transporter 1 (GLUT1)  in STZ treated cells 
compared to cells in the control medium without STZ was found. Data are presented as 
the relative mRNA expressions of IR, IGF1, GLUT1 or GLUT3 ± standard deviation (SD); *: 
p-value <0.05, #: 0.05<p-value <0.1. 
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3.2.6 Effect of STZ on the expression of insulin receptor protein in neural stem 
cells and differentiating cells 
In order to study whether STZ could influence the expression of insulin 
receptor also in vitro, we stained NSCs (Fig.27) and NSCs after incubation in 
differentiation medium for 2 days (Fig.27) with antibodies detecting the insulin 
receptor and counterstained with DAPI. For the the investigation of NSCs, we 
separated neurospheres into single cells and seeded them in a 24-well plate with 
pre-coated coverslips at 20,000 cells/well. After 2 days of incubation in proliferation 
culture medium with or with 2.5 mM STZ, we stained them for IR. In Fig.27A it can be 
seen that most of the NSCs express IR, when STZ is absent in the culture medium. 
Thus, most NSCs express insulin receptor under normal conditions. However, 
incubation of NSCs culture medium with 2.5 mM STZ  resulted in overall decreased 
number of NSCs and the percentage of NSCs with IR expression was decreased (to 
42.2%; p=0.003) (Fig.27D, Fig.29). 
 
Fig.27. The effect of STZ on Insulin receptor expression in neural stem cells 
We separated neurospheres into single cells and seeded them in a 24-well plate provided with 
pre-coated coverslips at 20,000 cells/well. After 2 days of incubation in proliferation culture 
medium without or with 2.5 mM STZ representative images (A-F) display that a high 
percentage of neural stem cells stained with 4',6-diamidino-2-phenylindole (DAPI) (B, Blue) 
were immunopositive for the insulin receptor (IR) (A, red; pink, C). After 2 days of 
incubation in medium containing 2.5 mM STZ not only the number DAPI-positive cells but 
also the number of double stained (IR and DAPI) cells is reduced. Scale bar in F=20 µm.  




For the analysis of differentiating cells, 10-15 neuropheres were plated into 
poly-L-ornithine/laminin-coated coverslips in a 24-well plate and were 
grown/incubated in differentiation culture medium with or without 2.5 mM 
STZ for 2 days. Our results revealed that two days after differentiation had 
started, most cells still express IR (Fig.28A-C). Other than the effect of STZ on 
NSCs, the expression of IR in differentiating cells seems to be unaffected by 
STZ treatment (Fig.28A-F). 
 
Fig.28. The effect of STZ on insulin receptor expression in differentiating cells 
10-15 neuropheres were plated onto poly-L-ornithine/laminin-coated coverslips in a 
24-well plate and were incubated in differentiation culture medium with or without 2.5 
mM STZ for 2 days. We then immunostained them with insulin receptor antibody (IR, red) 
and counterstained with 4',6-diamidino-2-phenylindole (DAPI) (blue). A-F: Representative 
images show that the number of differentiating cells and the expression of IR was not 
changed in STZ treated cells (D-F) compared to untreated cells (A-C). Scale bar in F=20 
µm.  




Fig.29. The impact of STZ on the percentage of Insulin receptor-positive neural stem cells and 
differentiating cells – a quantitative estimation 
The percentage of insulin receptor (IR)-expressing neural stem cells is reduced by 42.2% 
(p=0.003) in consequence of STZ treatment. In differentiating cells, no significant 
difference of the percentage of IR expression in STZ treated cells compared to cells in the 
control medium without STZ was found. Data are presented as the percentage of 
IR-positive cells ± standard deviation (SD); **: p-value <0.01.  
 
3.2.7 Effect of STZ on the expression of glucose transporter 3 protein in 
neural stem cells and differentiating cells 
In our study, we stained GLUT3 using immunofluorescence staining in both, 
NSCs and differentiating cells, comparable to what we did in with antibodies 
detecting the insulin receptor above (see Fig.27 and 28). For NSCs, we 
separated neurospheres into single cells and seeded them in 24-well plates with 
pre-coated coverslips at 20,000 cells/well. After 2 days of incubation in proliferation 
culture medium with 0 mM or 2.5 mM STZ, we stained them for GLUT3 (Fig.30). As 
shown in Fig.30A, GLUT3 is expressed in nearly all NSCs. However, two days of 
incubation in cell culture medium containing 2.5 mM STZ resulted in 
dramatically decreased number of immunostained cells expressing GLUT3 (a 
decrease of 61.7%; p=0.000064) compared to the controls (Fig.30D, Fig.32).  




Fig.30. The effect of STZ on Glucose transporter 3 expression in neural stem cells  
We separated neurospheres into single cells and seeded them in a 24-well plate provided with 
pre-coated coverslips at 20,000 cells/well. After 2 days of incubation in proliferation culture 
medium without (0 mM) or with 2.5 mM STZ we performed immunofluorescence staining using 
antibodies detecting the glucose transporter 3 (GLUT3; red) and counterstained with 
4',6-diamidino-2-phenylindole (DAPI) (blue). Representative images of 
GLUT3-immunopositive NSCs display that  under normal condition most neural stem 
cells express GLUT3 (A-C), and that STZ treatment did not only result in less GLUT3 
expressing NSCs, the percentage of GLUT3 expressing NSCs cells is found to be reduced 
(D-F). Scale=20 µm.  
 
For the analysis of GLUT3 expression in differentiating cells, we performed an 
experiment similar to our IR study in differentiating cells (see 3.26). 10-15 
neuropheres were plated onto poly-L-ornithine/laminin-coated coverslips in 24 
well plates and we let them grow in differentiation culture medium with or 
without 2.5 mM STZ for 2 days. Our results show that GLUT3 express in every 
differentiating cells (Fig.31A) and not only express in the cell body but also in 
the process of differentiating cells (Fig.31A). With 2.5 mM STZ treatment, 
some differentiating cells could not express GLUT3 (a decrease of 47.3%; 
p=0.015) (Fig.31D, Fig.32). 




Fig.31. The effect of STZ on Glucose transporter 3 expression in differentiating cells 
10-15 neuropheres were plated onto poly-L-ornithine/laminin-coated coverslips in a 
24-well plate and were incubated in differentiation culture medium with or without 2.5 
mM STZ for 2 days, so that the differentiation process started. These differentiating cells 
were then immunostained with glucose transporter 3 (GLUT3) antibodies (red) and 
counterstained with 4',6-diamidino-2-phenylindole (DAPI) (blue). Representative images of 
differentiating cells after GLUT3 immunofluorescence staining show that most of these 
cells express GLUT3 under normal conditions (A-C) and that STZ reduces the percentage of 
cells expressing GLUT3 (D-F). Scale bar =20 µm. 
 
 
Fig.32. The impact of STZ on the percentage of Glucose transporter 3-positive neural stem cells 
and differentiating cells – a quantitative estimation 
The percentage of Glucose transporter 3 (GLUT3)-expressing neural stem cells is reduced 
by 61.7% (p=0.000064) in consequence of STZ treatment. With regard to the percentage 
of differentiating cells a reduction of 47.3% (p=0.015) was found in STZ treated cells 
compared to cell in the control medium without STZ. Data are presented as the 
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percentage of GLUT3-positive cells± standard deviation (SD).*: p-value of t- test <0.05; 





In summary, our in vivo study revealed, that even if STZ icv treatment does not 
seem to considerably influence stem cell proliferation in the hippocampus, 
neither over a short-term period (1 month after STZ icv treatment) nor in the 
long-term (3 months after STZ icv treatment), the generation of immature and 
adult neurons is diminished in the hippocampus of rats 3 months after STZ icv 
treatment. This reduction detected after 3 months was specific for the septal 
hippocampus, discussed to be important for spatial learning. Applying double 
immunofluorescence staining using antibodies detecting BrdU (applied appr. 
27 days before sacrifice) and cell-type specific markers we found that STZ 
treatment does not affect the differentiation fate of newly generated cells. 
Phenotype analysis of BrdU-positive cells in the hilus and molecular layer 
revealed that some of the BrdU-positive cells are newborn oligodendrocytes 
but not newborn microglia. 
 
However, results of our in vitro study showed that STZ in the cell culture 
medium affects AN at different stages, during the proliferation of NSCs and 
during differentiation of their progeny. In more detail, I could show that STZ 
inhibits the proliferation of NSCs in a dose-dependent and time-dependent 
manner. In addition to what we could show in the in vivo study, that STZ 
treatment affects the number of newly generated neurons, the in vitro 
approach showed that STZ treatment does not affect the generation of new 
astrocytes. Trying to reveal cellular mechanisms underlying the negative 
influence of STZ on hippocampal AN, we performed qRT-PCR and 
immunofluorescence staining and found that in NSCs GLUT3 expression was 
reduced at the mRNA as well as protein level, but that the IR was found to be 
diminished only at the protein level after STZ treatment. QRT-PCR using primer 
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pairs specific for the detection of IGF1 and GLUT1 didn`t show mRNA 
expression differences between differently treated NSCs. Interestingly, the 
effect of STZ on differentiating cells seems to be different compared to the 
effect of STZ on proliferating NSCs, as in differentiating cells IR protein levels 
were not significantly changed in consequence of STZ treatment but GLUT3 
protein levels were shown to be decreased, too. 
  




4.1 In vivo study 
In our in vivo study, we analyzed hippocampal AN in STZ icv treated rats, an 
animal model for sAD. We focused on different AN stages, such as cell  (e.g. 
stem cell) proliferation, neuronal differentiation and cell survival to determine 
whether these AN phases are differentially affected by STZ icv treatment.  
 
4.1.1 STZ treatment does not affect the cellular fate of newborn cells  
We verified the birth of new neurons via double staining of BrdU-positive cells, 
which had survived up to 27 days, with NeuN, a marker for mature neurons, 
irrespective of the neuronal phenotype (e.g. excitatory glutamatergic neurons 
or inhibitory GABAergic neurons). As the percentage of newborn neurons 
(BrdU+/NeuN+) cells in relation to the number of BrdU+ cells was similar in all 
treatment groups, we could not reveal short-term or long-term effects of STZ 
icv treatment on the differentiation outcome. We disclosed that about 50% of 
all BrdU+ cells in the SGZ and GCL of the dentate gyrus also expressed NeuN, a 
percentage similar to the percentage reported by other groups (Aberg et al., 
2000, Malberg et al., 2000, Schmitt et al., 2007, Winner et al., 2012). 
Interestingly, irrespectively of the treatment group we always detected more 
long-term survived BrdU-ir cells in the hilus and ML of the DG than in the GCL 
including the SGZ (=SGZ/GCL). This distribution pattern of long-term survived 
BrdU-positive cells in the rat DG (ML>hilus>SGZ/GCL) resembles the 
distribution pattern found by Mandyam and coworkers in mouse DG 
(ML>hilus≥oGCL) (Mandyam et al., 2007). In contrast, Donavan and coworkers 
detected most of the surviving BrdU-positive cells in the SGZ, many cells in the 
ML and fewest in the hilus and oGCL (SGZ≥ML>oGCL≥hilus) (Donovan et al., 
2006). However, this almost exclusive distribution of BrdU+/NeuN+-cells in the 
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SGZ and GCL, and not in ML and hilus, reassured that the birth of neurons 
primarily happens in these neurogenic regions SGZ and GCL in rodents (Yagita 
et al., 2001, Donovan et al., 2006) as also found in humans (Eriksson et al., 
1998) and macaque monkeys (Kornack and Rakic, 1999). This regional 
distribution of AN is further supported by the fact that marker for immature 
neurons such as NeuroD (mitotic) and DCX (postmitotic), we also used in this 
study, are exclusively expressed in the SGZ/GCL in rodents (Takasawa et al., 
2002, Donovan et al., 2006), humans (Anacker et al., 2011) and monkeys (Ma 
et al., 2008). Although in our study the results of NeuroD and DCX stainings 
are similar, these two markers represent neuronal cells of different 
developmental stages.  
 
In the ML and hilus, we could show that some of these newborn and 28 days 
survived cells are oligodendrocytes using double immunofluorescence staining 
with antibodies detecting BrdU and APC, a marker for oligodendrocytes. In 
accordance with these findings, Kornack and Rakic detected some 
BrdU-labeled cells which also express two different markers for  
oligodendrocytes, O4 and CNP, in the hilus and ML of adult macaque monkeys 
(Kornack and Rakic, 1999). In a mouse study, cells co-labeled for BrdU and the 
oligodendrocyte marker NG2, were almost exclusively found in the ML (Bribian 
et al., 2012). This suggests that the birth of new oligodendrocytes in the ML 
and hilus may be a common phenomenon not only in our rat model, but also 
in mice (Bribian et al., 2012) and monkey (Kornack and Rakic, 1999). Loss of 
oligodendrocytes in the hippocampus in monkeys in consequence of STZ icv 
treatment has been found by Lee et al., whereas they did not show that STZ 
really affects the generation of new oligodendrocytes (Lee et al., 2014). In 
general, new oligodendrocytes can be generated from oligodendrocyte 
progenitor cells and NSCs In the adult brain, and several factors have been 
found to be involved in their production, such as EGF (Gonzalez-Perez et al., 
2009), sonic hedgehog (Lu et al., 2000), platelet-derived growth factor 
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(Woodruff et al., 2004), chordin (Jablonska et al., 2010) and sirtuin 1 (Rafalski 
et al., 2013).  
 
4.1.2 STZ icv treatment does not affect cell proliferation, but affects 
differentiation and survival of newborn cells, a later stage of adult 
neurogenesis 
In our quantitative immunohistochemistry study using antibodies detecting 
the proliferation marker MCM2 we could not reveal statistically significant 
differences between cell proliferations in the SGZ of STZ icv treated rats and 
the respective controls, neither in STZ 1 month groups nor in STZ 3 months 
groups. In accordance with our results Arabpoor and coworkers didn`t detect 
significant differences in the number of Ki67-positive cells, another frequently 
used marker for the detection of proliferating cells, 1 month after STZ icv 
treatment (Arabpoor et al., 2012). In contrast to our findings, Qu and 
coworkers showed that 20 days after STZ icv treatment the number of 
BrdU-positive cells was decreased (Qu et al., 2012). As they applied BrdU daily 
on 12 consecutive days before rats had been sacrificed their experimental 
design was not aimed solely at the analysis of stem cell proliferation, whereas 
their study results cannot be compared directly with our results.   
 
In contrast, we detected significantly decreased number of newly generated 
mitotic neuroblasts and postmitotic immature neurons as detected by NeuroD 
and DCX immunohistochemistry, respectively, in the septal hippocampus of 
rats 3 months after STZ icv treatment. This phenomenon of less immature 
neurons probably represents the source for the reduced number of BrdU-ir 
cells (survived for approximately 27 days) we have detected in the same part 
of the hippocampus. Based on this we conclude that the STZ icv treatment 
primarily affects AN at the level of differentiation and survival of newborn 
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cells. However, one month survival after STZ icv injections did not affect the 
number of NeuroD and DCX positive cells. Therefore, cognitive deficits already 
shown in rats 2-4 weeks after STZ icv injections (see introduction) do not 
correlate with AN changes in the brain of rats 1 month after STZ icv treatment, 
and at this early stage must have other neurobiological correlates than the 
decreasing number of differentiating newborn cells in rats 3 months after STZ 
icv treatment. As the concentrations of glucose and ATP are shown to be 
decreased in the cerebral cortex from 3 weeks following STZ icv administration 
on (Lannert and Hoyer, 1998), brain insulin receptor signaling dysfunction 
(Lannert and Hoyer, 1998), and a progressive increase of oxidative stress is 
also shown very early after STZ icv treatment (Ishrat et al., 2006, Khan et al., 
2012, Mansouri et al., 2013, Zhou et al., 2013) these biochemical changes 
could be responsible for the early cognitive decline. However, Rai et al. (2014) 
suggested that post-synaptic neurotoxicity is one key factor in STZ induced 
memory impairment. They showed spatial memory deficits in rats 14–16 days 
after STZ icv administration accompanied by reduced expression of 
post-synaptic marker CaMKIIα and PSD-95 in cortex and hippocampus, while 
pre-synaptic marker such as synaptophysin and SNAP-25 remained unaltered 
(Rai et al., 2014).  
As AN is decreased in rats 3 months, and not 1 month after STZ icv treatment, 
these changes resemble the timeline of morphological changes as congophilic 
Aβ aggregates in meningeal capillaries and intracellular Aβ42 accumulation in 
cerebral cortex were found not earlier than three months after STZ icv 
administration (Salkovic-Petrisic et al., 2006, Salkovic-Petrisic et al., 2007, 
Salkovic-Petrisic et al., 2011). Even more, diffuse Aß42-positive extracellular 
plaque-like formations in neocortex and hippocampus could not be detected 
earlier than 6 months (Knezovic et al., 2015). Therefore, only subtle effects of 
STZ icv treatment on Aß and Tau pathology, but extensive biochemical and 
behavioral changes are detectable already one month after STZ icv treatment, 
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whereas structural changes including the appearance of Aß42 accumulation 
and altered AN are detectable not before 3 months after STZ icv  treatment. 
Probably, an early stage of reversible cognitive impairment initially caused by 
synaptic dysfunction (Rai et al., 2014), energy deficits (Lannert and Hoyer, 
1998) and increasing oxidative stress (Ishrat et al., 2006, Khan et al., 2012, 
Mansouri et al., 2013, Zhou et al., 2013) and paralleled by subtle effects of STZ 
icv treatment on Aß and Tau patholoy could become irreversible in association 
with decreased AN and more comprehensive Aß42 changes. Therefore, 
reduced AN may maintain the cognitive decline and may contribute to its 
general progressivity and irreversibility found in later stages of AD.  
 
In mammals, stem cells in adult organs reside in specialized niches in close 
proximity to blood vessels - in so-called angiogenic niches (Palmer et al., 2000). 
Therefore, AN is controlled by factors derived from blood vessels and their 
microenvironment such as secreted neurotrohic and angiogenic factors (e.g. 
BDNF, VEGF, TGF-ß) (Goldberg and Hirschi, 2009, Goldman and Chen, 2011). As 
congophilic Aβ aggregation in the meningeal capillaries as well as diminished 
AN was detected in brains of rats 3 months after STZ administration  
(Salkovic-Petrisic et al., 2011), cerebral amyloid angiopathy could be discussed 
to comprehensively impact the phenomenon of AN in this animal model of sAD. 
A possibly altered angiogenic niche in AD was pointed to by a study of 
Boekhoorn and coworkers using human post mortem tissue of presenile AD 
patients as they detected increased Ki67 immunoreactivity in endothelial 
structures of AD patients compared to respective controls (Boekhoorn et al., 
2006). As vascular structure appears impaired in AD (Wu et al., 2005) 
increased Ki67 immunoreactivity in vascular cells may reflect an aberrant 
response that could contribute to vascular dysfunction. Boekhoorn and 
coworkers proposed that “vascular-associated Ki67 expression in the presenile 
AD hippocampus is either non-functional or even dysfunctional as vascular 
function is compromised in AD” (Boekhoorn et al., 2006).  




That energy metabolism, especially glucose metabolism and insulin receptor 
signaling, could have an influence on AN is substantiated by microarray studies 
performed by Geschwind et al. (Geschwind et al., 2001) and Ivanova and 
coworkers. They showed that proliferation of neural stem cells (NSCs) and the 
transition from a newborn undifferentiated cell to a differentiated (mature) 
neuron, astrocyte, or oligodendrocyte is accompanied by many changes of the 
expression of metabolism related genes such as Insulin-like growth factor 
binding protein 3, Cytochome c oxidase (Geschwind et al., 2001), Enolase 1, 
Acetyl-coenzyme A synthetase 1 and Pyruvate dehydrogenase E1 alpha subunit 
(Karsten et al., 2003). The Insulin/IGF-1 signaling pathway is central in 
coordinating energy taking and expenditure (Rafalski and Brunet, 2011). 
Although IGF-1 mRNA was detected in all regions of the neonatal brain,  there 
is considerable regional variation in the level of expression with highest 
expression levels in regions where neurogenesis persists after birth such as the 
hippocampus and the subventricular zone (Bartlett et al., 1991). The 
association of AN and insulin signaling pathways is substantiated by the fact 
that adult NSCs express the IGF-1 receptor (Aberg et al., 2003) and that the 
insulin gene can be activated by the transcription factor NeuroD (also called 
Beta2) (Naya et al., 1995).  
4.1.3 Hippocampal subregions were differently influenced by STZ icv 
treatment – which points to different connectivities and functions  
We analyzed the septal and temporal part of the hippocampus separately, as it is 
suggested that the hippocampus is functionally different along its septo-temporal 
axis (Moser and Moser, 1998) and that septal regions are involved mainly in learning 
(especially in spatial learning) and memory processes (Moser et al., 1995). The most 
prominent cortical projections from the septal CA1 and the septal parts of the 
subicular complex are to the retrosplenial and anterior cingulated cortices in rats 
                                                                                   Discussion 
89 
 
(Cenquizca and Swanson, 2007) and monkeys (Kobayashi and Amaral, 2007). These 
two cortical regions have been found involved primarily in the cognitive processing of 
visuospatial information and memory processing as well as environmental 
exploration (Fanselow and Dong, 2010). The temporal parts of 
hippocampal-subiculum complex send its projections to olfactory bulb together with 
several other primary olfactory cortical areas, and share massive bidirectional 
connectivity with amygdalar nuclei (Cenquizca and Swanson, 2007). These regions 
regulate the impact of emotional experiences and to control general affective states 
(Fanselow and Dong, 2010). Strongest long-term effects of STZ icv treatment on 
hippocampal AN were found in the septal hippocampus and STZ icv treatment is 
shown to result in spatial learning deficits which resembles the spatial memory 
deficits in AD patients. Our results regarding the different involvement of the septal 
and temporal hippocampus in neuroplasticity phenomena are in line with findings 
obtained by other AD researchers. Fuster-Matanzo and coworkers showed increased 
neurodegeneration in consequence of GSK3ß overexpression in mice exclusively in 
septal hippocampus (Fuster-Matanzo et al., 2011). In addition, increased CREB 
function was revealed exclusively in the CA1 region of septal hippocampus in 
TgCRND8 mice which was sufficient to restore function in neuronal structure, 
network activity as well as learning and memory (Yiu et al., 2011).  
 
The importance of AN for spatial learning is substantiated by the finding that the 
performance in a spatial learning test correlates with the number of NeuroD-positive 
cells, which are mitotic active neuroblasts, a pre-stage of the postmitotic immature 
neurons (Karabeg et al., 2013). Moreover, the study of human hippocampal 
neurogenesis by Coras and colleagues revealed that patients with low numbers of 
proliferating progenitor cells and newborn neurons showed more severe learning 
and memory impairments (Coras et al., 2010). As shown by the study of McClean and 
coworkers AN could not only play a role in the etiopathogenesis of AD, but also in the 
improvement of cognition (McClean et al., 2011). These authors were able to reveal 
improved learning and memory performances in TgAPP/PS1 mice after treatment 
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with liraglutide, a glucagon-like peptide-1 analog used for the treatment of diabetes, 
in parallel to an AN increase in the hippocampus. Similar effects were shown in 
TgAPP/PS1 transgenic mice after treatment with the neuroprotective Gingko biloba 
extract EGb 761 (Tchantchou et al., 2007).  
 
In conclusion, as hippocampal AN is demonstrated to be diminished in STZ icv 
treated rats (Fig. 30), a non-transgenic animal model for sAD, this in vivo study 
provides further evidence that hippocampal AN could be involved in the 
etiopathogenesis of sAD.  
 
4.2 In vitro study 
In our in vitro study, we analyzed the effect of STZ on the hippocampus-derived 
NSCs. We focused on different AN stages, such as stem cell proliferation, cell 
migration and neural differentiation, whether these AN phases are 
differentially affected by STZ treatment. Besides, we analyzed mRNA as well as 
protein expression of the insulin receptor (IR) and glucose transporter 3 
(GLUT3) in NSCs and differentiating cells. 
 
4.2.1 STZ treatment significantly decreases stem cell proliferation  
In our study, the number and size of neurospheres, the percentage of 
BrdU-labeled proliferating cells were shown to be dramatically decreased after 
STZ treatment. Although we could not exclude the possibility that the 
decreasing number and size of neurospheres are the results of cell death, the 
decreased number of BrdU marked cells indicate that at least the inhibition of 
proliferation is partly participating in the reducing of NSCs numbers. Our 
findings of a negative effect of STZ on proliferating cells is similar to the 
findings of Qu and colleagues, who detected significantly decreased number of 
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BrdU-positive cells in consequence of STZ treatment , but the concentration of 
STZ they used was 8 mM which is much higher than us (Qu et al., 2012).  
 
The decreasing of NSCs following STZ treatment may be linked to increased 
oxidative stress. Qu and colleagues showed that STZ elicits a striking increase 
of cellular reactive oxygen species (ROS) in NSCs (Qu et al., 2012). Although 
proliferative NSCs maintain high endogenous ROS status and pharmacological 
or genetic manipulations that diminished cellular ROS levels interfered with 
normal NSCs function both in in vitro and in vivo studies (Le Belle et al., 2011), 
too high ROS loading could cause cell death and have anti-proliferative effects 
on NSCs (Limoli et al., 2006). The in vitro study of Prozorovski and coworkers 
showed that NSCs exposed to pro-oxidative buthionine sulfoximine, an 
inhibitor of glutathione synthetase, that cause intracellular accumulation of 
ROS, causes a reduction in the number of NSCs (Prozorovski et al., 2008).  
4.2.2 STZ treatment does not affect the migration of differentiating cells 
According to our results, STZ does not affect migration of newborn cells. NSCs 
migration is an essential process for the development of the central nervous 
system (CNS) as well as for AN in the CNS of mammals (Hatten, 1999). Little is 
understood about the mechanism of controlling the migration of NSCs or 
neural progenitor cells in the adult brain. Neural progenitors transplanted into 
the brain were shown to migrate toward either localized (like stroke) 
(Arvidsson et al., 2002) or diffuse (like glioblastoma) (Glass et al., 2005) areas 
of brain damage. These studies suggest that factors such as 
neuroinflammatory response like tumor necrosis factor-α (TNF-α), interferon-γ 
(IFN-γ) and monocyte chemoattractant protein-1 (MCP-1) (Belmadani et al., 
2006), associated with damaged areas, can influence the migration of these 
differentiating NSCs. The level of TNF-α in hippocampus and cerebral cortex 
(Rai et al., 2014), and IFN-γ in peripheral blood lymphocytes (Pandey and Bani, 
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2010) were found to be increased in STZ icv treated rats. Whether these 
elevated TNF-α and IFN-γ levels affect the migration of NSCs is still uncertain. 
The results of our in vitro-investigations revealed that STZ in the culture 
medium did not affect the migration of new born cells . However, our assay 
measured migration of all of the new born and differentiating cells, 
irrespective of the final neural phenotype. However, we cannot exclude that 
STZ regulates migration of a particular cell type. 
 
4.2.3 STZ treatment affects the cellular fate of newborn cells in vitro 
We investigated whether STZ influences the differentiation process of in vitro 
cultivated NSCs to neurons and astrocytes via staining of Tuj-1 (a marker for 
immature neurons) and GFAP (a marker for astrocytes), respectively. In our 
quantitative study, STZ was found to dramatically reduce the number of 
Tuj-1-positive cells, but not the number of GFAP-positive cells. Therefore, in an 
in vitro approach STZ seems to affect the differentiation fate of newly 
generated cells. Similar to our results, Qu and colleagues found that STZ 
decreased the generation of new neurons via immunostaining with three 
neuronal markers, Tuj-1, microtubule-associated protein 2 (MAP 2) and 
neurofilament 150 (NF 150) (Qu et al., 2012). In our study we revealed that 
without any treatment about 15% of cells could be staining with Tuj -1 after 
two days of incubation in the differentiation medium, a percentage lower than 
the finding of Dong ’s (34%, differentiation for 3 weeks) (Dong et al., 2012) and 
Qu’s (20%, , differentiation for 7 days) (Qu et al., 2012). However, besides 
different times for the differentiation process in these studies, NSCs used of 
both of these two research groups were obtained from much younger rats (Qu: 
newborn rats at postnatal day 0; Dong:  E17 rats). That is why their study 
results cannot be compared directly with our results. As we had been 
interested in AN we had to use older (young adult) rats and not rats of an age 
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the other researchers used. Different from our results with Tuj-1 staining, our 
study revealed that STZ treatment has no significant influence on the 
percentage of GFAP-positive cells. About 20% GFAP positive cells are detected 
in both treatment groups, the STZ treatment group and the control group. Due 
to different ages of animals used, different percentages of GFAP-positive cells 
were detected. However, all known in vitro studies (including our in vitro study) 
reported about higher number of astrocytes compared to neurons (Tropepe et 
al., 1999, Horie et al., 2004, Schultz et al., 2011, Liu et al., 2014). As already 
mentioned above, STZ treatment increases ROS content in cultured NSCs (Qu 
et al., 2012). As increasing ROS content resulting from treatment with 
pro-oxidative bothionine sulfoximine or diethyldithiocarbamate was shown to 
decrease the proportion of neurons after 7 days of incubation of NSCs in 
differentiation medium (Prozorovski et al., 2008) ROS seem contribute to 
neural-fate decision. 
 
4.2.4 Insulin receptor and glucose transporter 3 is affected by STZ treatment 
 
Almost all NSCs incubated in culture medium without STZ were shown to 
express IR and GLUT3 proteins. However, NSCs incubated in culture medium 
containing 2.5 mM STZ resulted in a reduced number of cells exhibiting IR and 
GLUT3 protein expression. Interestingly，the gene expression of IR in NSCs was 
not significantly affected by STZ treatment. Thus, STZ may influence the 
process of IR protein translation, post-translational modification or 
distribution. It has been found that in the adult brain the insulin signal is 
needed to keep NSCs alive and keeping the IR expression in the brain prevents 
the die-off of NSCs in drosophila (Siegrist et al., 2010). Activation of the 
PI3K/Akt pathway downstream of the insulin/IGF receptors activation 
promotes the self-renewal of NSCs (Groszer et al., 2006). Thus, the inhibition 
of NSCs` proliferation after STZ treatment may be linked to the down 
regulation of IR as observed in our study. Adult NSCs express GLUT1 and 
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GLUT3 but not GLUT2 and GLUT4 (Maurer et al., 2006), so the “fuel” for NSCs 
depends on the transport of glucose via GLUT1 and GLUT3. Maurer and 
colleagues found that high glucose concentrations and hypoxia increase GLUT3 
protein concentration but do not significantly change the expression of GLUT1 
in NSCs (Maurer et al., 2006). Thus, GLUT3 may be more sensitive to 
environmental changes. There is only few literature available dealing with the 
topic of a relationship between NSCs` proliferation and GLUT3 expression. But, 
in non-small cell lung cancer, GLUT3 was found to be induced and to promote 
tumor cell proliferation (Masin et al., 2014). GLUT3 may also regulate NSCs 
proliferation through enhancement of the transport of glucose into the cells 
providing energy.  
 
My immunostaining study with differentiating cells revealed that the 
expression of GLUT3 is decreased after STZ treatment, at least in some of the 
differentiating cells. This may be one out of several reasons why STZ affects 
the differentiation fate of NSCs. Both, GLUT1 and GLUT3, are expressed in NSCs 
(Maurer et al., 2006), however, GLUT1 is the main glucose transporter in the 
plasmamembrane of astrocytes, whereas GLUT3 is the main glucose 
transporter of neurons (McCall et al., 1996, Dienel, 2012). The decreasing of 
GLUT3 expression may reduce the potential of NSCs toward neuronal-oriented 
differentiation without affecting the differentiation to astrocytes.  
 
4.3 The in vivo and in vitro study – similarities and differences of obtained 
results  
Both, the in vivo as well as the in vitro study, point to the fact that STZ diminishes 
hippocampal AN. However, as displayed in Fig. 33 A, the in vivo study revealed that 
STZ icv treatment primarily affects the differentiation process and the survival 
rate of newborn cells, whereas the in vitro study, as displayed in Fig. 33B, 
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showed that STZ affects both, the proliferation of NSCs and the differentiation 
and survival of newborn cells.  
 
Both approaches have their own advantages, e.g. in the in vivo study using 
hippocampal sections of the whole septal-temporal extension we were able to 
demonstrate that exclusively in the septal hippocampus (Fig. 33A) discussed to 
be important for spatial learning AN is hampered, and in the in vitro study cellular 
mechanisms underlying the observed impaired neurogenesis in the hippocampus of 
STZ-treated rats could be more easily studied. In this in vitro approach we were 
able to show that STZ inhibits the expression of IR in NSCs and GLUT3 in NSCs 
as well as in differentiation cells. 




Fig.33 Schematic of in vivo (A) and in vitro (B) study results of streptozotocin treatment on 
adult neurogenesis in the rat hippocampus 
A: The birth of new neurons in the adult hippocampus, is hampered in the hippocampus of rats 3 
months, but not 1 month, after STZ icv treatment. Analyzing different AN-stages we revealed 
that STZ icv treatment primarily affects the differentiation process and the survival rate 
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of newborn cells. Both of long term and short term STZ icv treatment could not affect 
proliferating cells. We could also show that STZ exerts its biggest effects on the septal 
hippocampus, which is important for learning and memory processes and therefore is in 
line with spatial learning deficits obvious in AD patients.  
B: In the in vitro approach STZ could inhibit AN in several different stages, including cell 
proliferation and differentiation. Moreover, we were able to show that STZ tre atment 
seems to affect the differentiation fate of newly generated neurons but not of astrocytes. 
We could also show STZ inhibits the expression of IR in NSCs and GLUT3 in NSCs as well 
as in differentiation cells.  
 
Different results from in vivo and in vitro studies are quite common in biological 
studies, especially in medical, pharmacological and toxicological research. 
Toxicological study revealed that non-genotoxic rat liver carcinogen methapyrilene 
alters the expression of the metabolizing genes sulfotransferase family, cytosolic, 1A, 
phenol-preferring, member 1 (SULT1A1) and 4-aminobutyrate aminotransferase 
(ABAT) as well as the growth arrest and DNA damage gene (GADD)34 in vitro, but not 
in vivo (Schug, et al., 2013). The observed in vivo/in vitro discrepancies always can be 
explained by different pharmacokinetics present in vivo and in vitro (Schug, et al., 
2013). However, in other studies without involved in pharmacokinetics, discrepancy 
can also be found. For example, Desestret and coworkers showed that macrophages 
provided potent protection against neuron cell loss through a paracrine mechanism 
in the in vitro model of cerebral ischemia, however, in the in vivo model this 
cell-based treatment did not significantly improve any outcome measure compared 
with vehicle (Desestret, et al., 2013). The reason for the discrepancy in the studies 
like above may then be more complicated. 
 
Discrepancy of our in vivo and in vivo results may originate in the different 
complexity of the NSCs proliferation and the growth and differentiation 
environment. In our rat model, STZ regulating AN may not target NSCs directly 
but also through effecting other cells, and influencing this micro-environment. 
However, for in vitro study, micro-environment for NSCs proliferation is almost 
missing and STZ targets NSCs and differentiating cells directly. In an in vivo 
condition, NSCs are surrounded by astrocytes, mature granule cells and resting 
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in close proximity to blood vessels and all these constitute a complex 
micro-environment for AN in the SGZ (Palmer et al., 2000). Micro-environment 
is important in the facilitation of the survival and self-renewing capacity of the 
stem cells (Kazanis et al., 2008) that depends on the change of vasculature 
(Palmer et al., 2000), growth and trophic factor (Anderson et al., 2002, Lee et 
al., 2002) and glial support cells (Morrens et al., 2012). In animal model 
studies, STZ does not only influence NSCs but also other type of cells like 
inducing neuronal apoptosis (Unsal et al., 2013), astrogliosis and microglial 
activation (Chen et al., 2013). Apoptotic neurons could secrete many factors 
[like high mobility group box 1 (HMGB1) and TNF-α (Kawabata et al., 2010)] 
and these factors are also shown to regulate AN. HMGB1 has been found to 
promote neurogenesis in later phases of intracerebral hemorrhage (Lei et al., 
2015). Activated glial cells secrete cytokines like CD11b and TNF-α (Rai et al., 
2014). Recently, It was reported that active microglia could enhance 
neurogenesis and pharmacological suppression of producing proinflammatory 
cytokines (i.e., IL-1β, IL-6, TNF-α, and IFN-γ) significantly inhibited 
neurogenesis in the SVZ (Shigemoto-Mogami et al., 2014). Furthermore, 
growth and trophic factors such as insulin/IGF (Grunblatt et al., 2007), NGF 
(Hellweg, 1994) as well as BDNF (Shonesy et al., 2012) are shown to be altered 
in the STZ icv rat model, which dramatically influence AN already described in 
our introduction part.  
 
In summary, we speculate the discrepancy found in our in vivo/in vitro study 
may due to the complex micro-environment of AN niche in our in vivo study 
but missing in our in vitro study. 
  




As neuropathological changes already observed 3 months following STZ icv 
treatment are shown to become more and more apparent in brains of rats with 
increasing survival times, the analysis of hippocampal AN in rats 6 and 9 months 
after STZ icv treatment seems to be mandatory for a more comprehensive 
understanding of the involvement of AN in the etiopathogenesis of sAD.   
Regarding the in vitro study, there are still many unresolved issues needed to 
be further clarified. For instance, we only clarified that proliferation, 
differentiation as well as the expression of IR and GLUT3 protein were affected 
by the treatment with STZ. But, a causal relationship between them is not 
proven, yet. In future, we could continue to study these through gene 
knockout/overexpression of IR and GLUT3 and/or pharmacological inhibition of 
the IR [such as: insulin receptor-specific tyrosine kinase inhibitor, 
HNMPA-(AM)3]. 
 
In order to solve the discrepancies between the results of the in vivo study and 
in vitro study, we could use for future in vitro work the rat as old as in vivo 
study. We also could perform muti-cells co-culture systems, for instance, NSCs 
co-cultured with neurons, astrocyte or microglia. Then, the influence of 
micro-environment for NSCs could be studied in the treatment of STZ. 
As factors and mechanisms underlying the formation and survival of new 
neurons in the adult brain certainly are of potential therapeutic importance 
especially for the treatment of sAD, in future, we could use our in vivo and in 
vitro system to help discovering new drugs. It would be worth testing drugs 
already shown to prevent cognitive deficits in this STZ icv model  and cell 
model [such as treatment with galactose (Salkovic-Petrisic et al., 2014); 
curcumin (Isik et al., 2009); selenium (Ishrat et al., 2009); rhodiola crenulata 
extract (Qu et al., 2009); cyclooxygenase inhibitors (Dhull et al., 2012) on their 
effectiveness on AN. 
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